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Introduction
Parasites of the order Kinetoplastida are the causative agents
of a number of human and animal diseases including Human
African Trypanosomiasis (HAT) (caused by Trypanosoma brucei
rhodesiense and T. b. gambiense), Chagas’ disease (T. cruzi) and
the leishmaniases (Leishmania sp.). Collectively these diseases
have a large unmet disease burden,
[1] with the current thera-
peutics used to treat them possessing severe limitations.
[2] All
of these trypanosomatid parasites use a trypanothione-based
redox metabolism,
[3] which is absent in humans. The enzymes
of this redox pathway are therefore considered to be attractive
targets for the development of new antitrypanosomatid
drugs.
[4]
One component of the trypanothione-based redox pathway
is trypanothione reductase (TryR), which is responsible for re-
ducing trypanothione disulfide to the dithiol trypanothione
and in doing so provides reducing equivalents to protect the
parasites from oxidative damage.
[3] In T. brucei it has been dem-
onstrated that TryR activity is required for parasites to grow in
culture and to be infective in a mouse disease model.
[5] There-
fore, TryR is a validated drug target, and there are a number of
recent reports outlining the discovery and development of
ACHTUNGTRENNUNGinhibitors of this key enzyme.
[6]
A recently reported high-throughput screening (HTS) of
known bioactive compounds against T. cruzi TryR identified a
number of novel TryR inhibitors
[7] including the arylcyclohexyl-
amine BTCP
[8] (1, 1-(1-benzo[b]thiophen-2-yl-cyclohexyl)-piperi-
dine). BTCP (1) is an analogue of the anaesthetic drug PCP (2,
1-(1-phenyl-cyclohexyl)-piperidine, phenylcyclidine). However,
despite the structural similarity between compounds 1 and 2,
they have been shown to possess a different pharmacological
selectivity.
[8] BTCP (1) is a more potent dopamine uptake inhibi-
tor and has a much lower affinity for the PCP receptor.
BTCP (1) was considered to be a promising screening hit for
further development due to its low molecular weight (299),
low micromolar potency against T. cruzi TryR (IC50=3.7 mm), a
promising ligand efficiency (0.35 kcalmol
 1L), lack of activity
against the human homologue of TryR, glutathione reductase
(GR), and the fact that phencyclidines are known to cross the
blood–brain barrier, an essential property for the successful
treatment of stage 2 HAT. BTCP (1) also has the advantage of
being a druglike molecule, in contrast to some of the more
potent reported TryR inhibitors, many of which are polyamine
analogues
[6a,d,f] designed to mimic the spermidine moiety of
the enzyme substrate trypanothione. In addition, there are a
number of publications relating to BTCP (1) and other phency-
clidines detailing both synthetic strategies for analogue syn-
thesis and their associated pharmacological activities.
[9]
Due to the limitations of the current treatments for HAT,
there is a need for the identification of new compound classes
displaying antitrypanosomal activity. Therefore, a systematic
structure–activity relationship (SAR) analysis of BTCP (1)w a s
undertaken to optimise activity against both TryR and the
intact parasite T. brucei. The results of these investigations are
reported herein.
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Thirty two analogues of phencyclidine were synthesised and
tested as inhibitors of trypanothione reductase (TryR), a poten-
tial drug target in trypanosome and leishmania parasites. The
lead compound BTCP (1, 1-(1-benzo[b]thiophen-2-yl-cyclohex-
yl) piperidine) was found to be a competitive inhibitor of the
enzyme (Ki=1 mm) and biologically active against bloodstream
T. brucei (EC50=10 mm), but with poor selectivity against mam-
malian MRC5 cells (EC50=29 mm). Analogues with improved en-
zymatic and biological activity were obtained. The structure–
activity relationships of this novel series are discussed.
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Biological characterisation of
BTCP
In order to determine the validi-
ty of BTCP (1) as a starting point
for a target-driven approach to-
wards the identification of a lead
compound for the treatment of
HAT, the inhibitory activity of
BTCP against T. brucei TryR had
to be determined. BTCP (1)w a s
assayed against T. brucei TryR
using a HTS format based on a
published nonenzymatically cou-
pled assay
[10] and found to have
an IC50 value of 3.3 mm, confirm-
ing its suitability for further in-
vestigation. There is no signifi-
cant difference between the IC50
values for 1 against T. cruzi
(IC50=3.7 mm) and T. brucei TryR
(IC50=3.3 mm), which is as ex-
pected given the high degree of
sequence identity between TryR
in the two species (83% at the
amino acid level). A more detailed kinetic analysis established
that BTCP is a linear competitive inhibitor of TryR (with respect
to trypanothione), with a Ki value of 1.00 0.08 mm, in good
agreement with the IC50 value determined in the HTS-format
TryR assay.
BTCP (1) was assayed against bloodstream form T. brucei
brucei cells in a HTS-assay format and found to have an EC50
value of 10 mm, in close agreement with the previously pub-
lished EC50 value of 14 mm.
[7] BTCP (1) was screened against
MRC-5 cells in the same 96-well format as for the trypanosome
assay giving an EC50 value of 29 mm. Unfortunately, the three-
fold selectivity between MRC-5 and T. brucei is suboptimal, but
the selectivity is sufficient to warrant further development of
the compound series.
Synthesis of BTCP analogues
There are insufficient commercially available analogues of
BTCP (1) to establish a comprehensive SAR. Therefore, a chemi-
cal synthesis programme was required to support the develop-
ment of the hit compound. Initial synthetic studies focussed
on preparing a diverse collection of BTCP analogues systemati-
cally modifying the benzo[b]thiophene group, the piperidine
ring and the cyclohexyl ring (Table 1). In particular we were in-
terested in carrying out the following modifications to probe
for new interactions with the protein: changing the benzo[b]-
thiophene to other aromatic rings, both monocyclic and bicy-
clic; modifying the size of the piperidine ring and putting het-
eroatoms into the ring; modifying the size of the cyclohexyl
ring and adding substituents to it.
Two different synthetic methodologies were employed to
prepare the initial collection: first, addition of aryl lithiums to
the benzotriazole adducts of enamines
[11] (Scheme 1, route A);
and second, the reaction of aryl Grignards with a-amino nitriles
(the Bruylants reaction,
[12] Scheme 1, route B). Route A was suc-
cessfully employed in reactions where the aryl group was an
unsubstituted monocyclic aromatic (2 & 3), or when the aryl
group was a 5/6 fused bicyclic aromatic (e.g. benzo[b]thio-
phene, compounds 10, 13–15 & 17). The only exception to the
latter observation was that when 1-methylindole was em-
ployed in the reaction only a trace amount of the target mole-
Table 1. Analogues of BTCP (1) and their inhibitory activities against T. brucei TryR and in cell-based assays. See
Scheme 1 for the structure of analogues 1–19 and Scheme 2 for 23–25.
Compd Ar X Y n
1 n
2 TryR
IC50 [mm]
T. brucei
EC50 [mm]
1 (BTCP) 2-Benzo[b]thiophene CH2 CH2 1 1 3.3
[a] 10
[b]
2 (PCP) Benzene CH2 CH2 1 1 57 ND
3 2-Thiophene CH2 CH2 11 >100 ND
4 4-Phenyl-benzene CH2 CH2 11 >100 ND
5 2-Benzo[b]furan CH2 CH2 1 1 4.4
[c] 18
6 1-Naphthylene CH2 CH2 11 >100 ND
7 2-Naphthylene CH2 CH2 1 1 28 ND
8 2-(1-Methylindole) CH2 CH2 1 1 36 ND
9 2-Benzo[b]thiazole CH2 CH2 11 >100 ND
10 3-Benzo[b]thiophene CH2 CH2 1 1 60 ND
11 2-(3-Bromobenzo[b]thiophene) CH2 CH2 1 1 16 ND
12 2-(5-Bromobenzo[b]thiophene) CH2 CH2 11 >100 ND
13 2-Benzo[b]thiophene CH2 CH2 0 1 0.91
[d] 5.0
14 2-Benzo[b]thiophene – CH2 1 1 5.0 13
[e]
15 2-Benzo[b]thiophene O CH2 11 1 1 3 7
16 2-Benzo[b]thiophene NCH3 CH2 1 1 10 2.1
[f]
17 2-Benzo[b]thiophene CH2 CH2 10 1 1 3 5
18 2-Benzo[b]thiophene CH2 NCH3 1 1 0.93 ~15
[g]
19 2-Benzo[b]thiophene CH2 n/a 1 n/a 15 27
23 n/a CH2 CH2 11 >100 ND
24 n/a CH2 CH2 11 >100 ND
25 n/a CH2 CH2 11 >100 ND
[a] TryR Ki 1.00 mm. [b] MRC-5 EC50 29 mm. [c] TryR Ki 1.46 mm. [d] TryR Ki 0.26 mm. [e] MRC-5 EC50 22 mm. [f] MRC-
5E C 50>50 mm. [g] MRC-5 EC50>15 mm.N D=not determined. n/a not applicable, structures shown in full.
Scheme 1. Routes to BTCP analogues 2–19.
[11,14,15] See Table 1 for details of
analogue structures. Reagents and conditions:a )1 .1 H-benzotriazole, Et2O,
258C, 1 h; 2. ArLi, Et2O, 0!258C, 16 h; b) acetone cyanohydrin, DMF, MgSO4,
508C, 2–4 d; c) ArMgBr, Et2O, 358C, 16 h.
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substituted phencyclidines (6 & 7) via route A were unsuccess-
ful. Preparation of PCP (2) from phenyllithium also proceeded
in poor yield, suggesting that the Route A methodology is not
suited to the synthesis of analogues where a substituted ben-
zene ring is directly attached to the piperidylcyclohexyl moiety.
This observation may explain why when 5-bromobenzo[b]thio-
phene was employed as the substrate for lithiation the exclu-
sive product of the reaction was the bromine-substituted BTCP
analogue 12, possibly due to the failure of the generated ben-
zo[b]thien-5-yl-lithium species, but not the 5-bromobenzo[b]-
thien-2-yl-lithium species, to react. In contrast, both analogues
10 and 11 were isolated when 3-bromobenzo[b]thiophene was
employed, due to reactive species formed by lithiation at the
2 position in addition to lithium halogen exchange at the 3 po-
sition. The enamine building blocks required for the route A
synthesis were obtained from commercial sources, or readily
prepared using published methodologies.
[13]
Analogues 4, 6 and 7 have previously been prepared via the
Bruylants reaction (route B), therefore, they were prepared fol-
lowing this procedure.
[14] Attempts to prepare the 3-phenyl-
benzene isomer of 4 using this methodology were unsuccess-
ful. The indole-containing analogue 8 was also prepared using
this procedure. Route B has previously been utilised for the
preparation of the amine-containing analogue 16,
[15] therefore,
this route was chosen in preference to route A (Scheme 1). Ad-
ditionally, the amine-containing analogue 18 was prepared
using the Bruylants reaction as the requisite a-amino nitrile 22
was considered to be more synthetically accessible than the
substituted enamine that would be required to use route A
(Scheme 1).
In addition, analogues containing a carbonyl “spacer” be-
tween the cyclohexylpiperidine core and the aromatic func-
tionality were prepared by reaction of aryl lithiums with alpha-
amino nitrile 20 (Scheme 2).
[16] Further reaction of 23 with phe-
nyllithium gave an analogue containing two aryl groups (25).
Trypanothione reductase assay of BTCP analogues
Analogues 2–25 were tested for their ability to inhibit T. brucei
TryR (Table 1) using the HTS assay format previously employed
to assay BTCP (1). None of the aryl analogues (compounds 2–
12) showed an improvement in potency over the hit com-
pound 1. Analogues where the benzo[b]thiophene was re-
placed with a monocyclic aromatic (compounds 2–4) showed
a dramatic reduction in potency against TryR (IC50 values 57 to
>100 mm), suggesting a requirement for a fused bicyclic aro-
matic moiety for optimal inhibitor binding. The inhibition
values from analogues containing alternative fused bicyclic sys-
tems (compounds 5–10) suggest that there is a very specific
requirement for a 2-benzo[b]thiophene substitution, as demon-
strated by testing close isosteres such as 2-naphthyl (com-
pound 7,I C 50=28 mm vs 3.3 mm) and analogues containing
minor changes in inhibitor structure for example, compound 9
where the benzo[b]thiophene is replaced with a benzo[b]thia-
zole (IC50>100 mm). Indeed, with the exception of replacing 2-
benzo[b]thiophene with 2-benzo[b]furan (compound 5) all of
the aromatic analogues of BTCP (1) were at least one order of
magnitude less potent against T. brucei TryR (IC50 values 28 to
>100 mm). The screening results for analogues 11 and 12 dem-
onstrate that it is not possible to substitute 2-benzo[b]thio-
phene at the 5 position, but that substitution at the 3-position
gives analogues that retain some activity, albeit reduced. Given
these results no further exploration of the aromatic moiety
was conducted and all subsequent analogues would incorpo-
rate the 2-benzo[b]thiophene functionality.
Analogues 13–16 were prepared to investigate the effect of
changing the piperidine ring of BTCP (1). Exchanging the pi-
peridine for a morpholine or piperazine ring (compounds 15 &
16) results in a threefold reduction in potency (Table 1), possi-
bly due to the attenuated basicity of the nitrogen atom, or
due to the introduction of an additional polar atom (or a com-
bination of both). The acyclic diethylamino analogue (14)i so f
approximately equal potency to the hit compound 1 (IC50=
5.0 mm vs 3.3 mm). Unfortunately, attempts to prepare more
highly substituted acyclic analogues of 1 using route B
(Scheme 1) proved unsuccessful. The pyrrolidine-containing an-
alogue 13 was marginally more potent than the hit compound
(1) (IC50=0.91 mm vs 3.3 mm). A full kinetic analysis of analogue
13 showed it to be a linear competitive inhibitor with respect
to trypanothione (Ki=0.26 0.01 mm vs 1 mm for BTCP), con-
firming this mode of inhibition within the BTCP compound
series (Figure 1). However, this fourfold increase in potency did
not warrant any additional investigation into replacing the
ACHTUNGTRENNUNGpiperidine moiety.
The investigation of BTCP cyclohexyl-analogues was limited
by synthetic considerations, with just three analogues (17–19)
being prepared. Altering the cyclohexyl moiety by either ring
contraction to a cyclopentane ring (17), or by replacement
with a gem dimethyl substitution (19) gave analogues that
were three or fivefold less potent, respectively. This suggests
that the cyclohexane ring contributes to inhibitory activity by
either hydrophobic interactions, or by controlling the orienta-
tion by which the other moieties are presented to the protein.
The amine-containing analogue 18 showed a slight improve-
ment in potency (IC50=0.93 mm vs 3.3 mm) suggesting that it
may be possible to introduce a substituted nitrogen at the 4-
position of the cyclohexane moiety. Additionally, it may be
possible to substitute a carbon atom at the 4 position.
The “spacer”-containing analogues 23–25 were all found to
be inactive in the T. brucei TryR assay (IC50>100 mm). Therefore,
Scheme 2. Route to BTCP analogues containing a one carbon “spacer” be-
tween the piperidylcyclohexyl and aryl moieties.
[16] Reagents and conditions:
a) 1. ArLi, Et2O,  78!08C, 5–16 h, 2. aq HCl, 08C, 30 min; b) PhLi, Et2O, 0!
258C, 2.5 h.
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ACHTUNGTRENNUNGpiperidine core is probably an absolute requirement for TryR
ACHTUNGTRENNUNGinhibition within this series. The inactivity of these analogues
combined with the failure to significantly increase potency by
substitution of the aromatic, or piperidine moieties, meant
that substitution at the 4-position of the cyclohexyl ring
became the only focus of further investigations (see below).
Cell-based assays of BTCP analogues
A subset of the analogues prepared as part of the initial di-
verse BTCP analogue collection (compounds 1, 5 & 13–19)
were assayed for their ability to inhibit the growth of T. brucei
in culture (Table 1). With the exception of compound 16, the
analogues displayed a decrease in potency between the
enzyme and cellular assays of between 2- and 15-fold. Al-
though it is not possible to draw a reliable correlation with
this small subset, this level of decrease and its consistency be-
tween analogues suggests that inhibition of TryR could be the
cause of the inhibition of parasite growth and that it is not the
result of an off-target effect.
Additional analogues (14, 16 & 18) were subjected to the
MRC-5 counter screen and their selectivity between MRC-5
cells and T. brucei was found to be ~1- to >20-fold. Although
this low selectivity is disadvantageous, it may increase in ana-
logues with improved inhibitory activity against TryR.
Synthesis and TryR assay of BTCP analogues substituted at
the 4-position of the cyclohexyl ring
Two strategies were employed to functionalise the 4-position
of the cyclohexane moiety; first, preparation of a bipiperidinyl
analogue (28), with subsequent derivatisation of the nitrogen
atom, allowing the synthesis of a number of analogues with a
minimal number of synthetic transformations (Scheme 3); and
second, a stepwise preparation of cis and trans 38 containing a
tert-butyl substitution at C4 of the cyclohexane ring
(Scheme 4).
In order to prepare the bipiperidinyl 28 it was necessary to
employ a suitable protecting group for the nitrogen atom. Pre-
viously it has been reported that both the benzyl and benzoyl
nitrogen protecting groups are unsuitable for the preparation
of substituted phencyclidines.
[9a] Therefore, the Boc protecting
group was employed during the Bruylants reaction giving the
key protected intermediate 27 (Scheme 3). The Boc group of
27 was deprotected under acidic conditions to yield the secon-
dary amine 28, which subsequently underwent either acylation
or alkylation reactions to give the substituted analogues 29–
Figure 1. Kinetic analysis of inhibition of T. brucei TryR by analogue (13).
Global fit of data to linear competitive inhibition model presented as a Line-
weaver–Burke transformation. Inhibitor concentrations: 0, *; 0.19 mm, *;
0.39 mm, &; 0.77 mm, &.
Scheme 3. Synthesis of BTCP analogues containing a substituted nitrogen
atom at the 4-position of the cyclohexyl moiety. See Table 2 for a list of R
groups. Reagents and conditions: a) piperidine, acetone cyanohydrin, DMF,
MgSO4,5 08C, 4 d; b) benzo[b]thien-2-yl-MgBr, Et2O, 358C, 16 h; c) TFA,
CH2Cl2,08C, 1 h; d) R’COCl, DMAP, pyridine, 258C, 16 h; e) R’X, K2CO3,C H 3CN,
828C, 16 h; f) LiAlH4, THF, 408C, 0.5–3 h.
Scheme 4. Synthesis of cis and trans-4-tert-butyl cyclohexyl BTCP analogues
(38).
[9b] Reagents and conditions: a) benzo[b]thien-2-yl-CeCl2, THF,  78!
258C, 16 h; b) 1. TCA, NaN3, CHCl3,  25!08C, 55 min; 2. LiAlH4, THF, 258C,
2 h; c) 1,5-dibromopentane, K2CO3,C H 3CN, 828C, 3.5 d.
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ing to the formation of significant quantities of quaternary
ACHTUNGTRENNUNGammonium salts as side products, which proved difficult to
separate from the tertiary amines by column chromatography.
Therefore, LiAlH4 reduction of the amide analogues 30 and 32
was used to prepare the tertiary amine analogues 34 and 35,
respectively.
Analogues 27–35 were assayed for their ability to inhibit
T. brucei TryR as described above and the results are displayed
in Table 2. The free amine 28 was approximately equal in activ-
ity to BTCP (1) (IC50=5.1 mm vs 3.3 mm), suggesting that the in-
creased activity of the N-methyl analogue 18 is derived from
the introduction of the methyl group, not through the intro-
duction of a hydrogen bond donor. However, analogues con-
taining larger hydrophobic amide or alkyl substitutions (ana-
logues 29–31 & 34) all possessed reduced inhibitory activity
(IC50=6.6–19 mm). Similarly the Boc protected precursor 27
proved to be completely inactive in the TryR assay (IC50>
100 mm). This demonstrates that the 4-position of the cyclohex-
ane ring of BTCP (1) is not fully occluded by TryR upon inhibi-
tor binding, but that the protein region around this position
does not form favourable hydrophobic interactions. This con-
clusion is supported by the fact that analogues 32 and 33 con-
taining polar substitutions were found to be approximately
equipotent with BTCP (1) (IC50=2.6 mm and 4.4 mm, respective-
ly vs 3.3 mm), and of similar potency to the N-methyl analogue
18. Analogue 35 was found to be inactive in the TryR assay in-
consistent with the results observed for 32 and 33. However,
this lack of activity could be due to 35 being the only ana-
logue to contain three highly basic atoms.
Analogues 28 and 30–34 were assayed against T. brucei par-
asites and MRC-5 cells (Table 2). With the exception of com-
pound 32, all of the analogues showed some degree of selec-
tivity against the parasites (>2-fold). However, as observed
with the N-methyl analogue 16, compounds 28, 30, 31 and 34
showed improved potency in the T. brucei assay over the
enzyme assay. This is suggestive of either selective uptake, or
an off-target effect for these analogues.
Analogues containing alkyl substitutions at C4 of the cyclo-
hexyl ring have been previously prepared by employing either
the Bruylants reaction (Scheme 1, route B), or in a stepwise se-
quence from tertiary benzylic alcohols (e.g. 36) (Scheme 4). It
has been demonstrated that the Bruylants reaction gives only
a single isomer (cis) when 4-substituted a-aminonitriles are
used as the substrates for the reaction.
[17] However, there was
an interest in assaying both isomers of 38 as they have been
shown to possess a different pharmacological selectivity
[18] and
could offer an insight into the optimal arrangement of the pi-
peridine ring, aromatic group and 4-cyclohexyl substituent rel-
ative to each other for the inhibition of TryR. Therefore, in
order to access both isomers, a modification of the published
synthetic route outlined in Scheme 4 was employed. The two
isomers, cis-a n dtrans-38, were separated by column chroma-
tography at the final step. It has been demonstrated that the
cis isomer elutes first when the mixture is purified with silica as
the stationary phase.
[9b]
Cis-a n dtrans-38 were assayed for their ability to inhibit
TryR under the standard assay conditions and found to have
IC50 values of >100 mm and 3.6 mm, respectively. This demon-
strates that there is an absolute requirement for the piperidine
moiety to be equatorial and conversely for the aromatic
moiety to be in an axial conformation in order for BTCP ana-
logues to inhibit TryR. Additionally, these results show that
substituting BTCP with a bulky tert-butyl group at the 4-posi-
tion of the cyclohexane ring leads to no appreciable change in
TryR inhibitory activity (3.6 mm vs 3.3 mm for 1), supporting the
conclusion that the 4-position is not occluded by the protein
structure upon binding of the inhibitor with TryR. Trans-38 was
also screened in the cell assay and found to have an EC50 value
of 3.2 mm against T. brucei and inactive against the mammalian
cell line (EC50>15 mm), again comparable to 1.
Conclusions
The investigations reported herein have confirmed that ana-
logues of BTCP (1) represent a new class of TryR inhibitors,
which are to our knowledge structurally distinct from inhibitors
previously reported in the literature. Enzyme and cellular
assays have demonstrated that analogues of this series are
competitive inhibitors with respect to the natural TryR sub-
strate, trypanothione, and that the analogues are marginally
more potent against trypanosomes than mammalian cells in
culture.
Synthesis and screening of a diverse analogue collection has
allowed a detailed SAR to be established for all moieties of the
arylcyclohexylamine pharmacophore (Figure 2). However, al-
though the essential structural features for maintaining the in-
hibitory activity of BTCP analogues have been determined, no
functional group changes that significantly increase the poten-
cy against TryR have been identified.
From the rough correlation between T. brucei TryR IC50 and
T. brucei EC50 values it is expected that TryR inhibitors in the
single nanomolar range will be a requisite for adequate inhibi-
tion of parasite growth. However, given the preliminary SAR
this goal is unlikely to be realised without the aid of a protein–
ligand structure to identify potentially beneficial binding inter-
actions. However, no noncovalent protein–ligand structures
Table 2. Substituted analogues of BTCP (1) and their inhibitory activities
against T. brucei TryR.
[a]
Compd R
[b]
IC50 [mm]
T. brucei
EC50 [mm]
MRC5
EC50 [mm]
27 Boc >100 ND ND
28 H 5.1 2.5 11
29 COCH3 6.6 ND ND
30 COPh 13 6.5 >50
31 COCH2Ph 12 4.3 >50
32 COCH2NACHTUNGTRENNUNG(CH3)2 2.6 13 18
33 CH2CH2-N-Morpholine 4.4 20 >50
34 CH2Ph 19 15 >50
35 CH2CH2NACHTUNGTRENNUNG(CH3)2 >100 ND ND
[a] ND=not determined. [b] For full structures see Scheme 3.
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ed that submicromolar inhibitors of TryR can be developed,
[19]
these inhibitors are not considered druglike (e.g. MW>500).
This requirement for high molecular weight compounds to effi-
ciently inhibit TryR may be a direct consequence of TryR pos-
sessing a large, solvent-exposed active site.
[20] To date, druglike
molecules have only achieved potencies in the low micromolar
range,
[6] unfortunately this remains true for the BTCP series.
Experimental Section
Biology
TryR enzyme assay
A nonenzymatically coupled assay for detecting TyrR activity was
used.
[10] In this assay, the activity of TyrR is coupled to the reduc-
tion of DTNB (5,5’-dithiobis-(2-nitrobenzoic acid)) to 2TNB
  by dihy-
drotrypanothione (T[SH]2). Formation of 2TNB
  is measured as an
increase in absorbance at 412 nm (Figure 3). The TyrR screening
assay was miniaturised and optimised to a 384-well plate format.
Assessment of the assay for robustness in an automated environ-
ment yielded the following typical performance statistics: Z’=
0.84 0.001; %CV (plate)=3.65 0.4; signal to background=10 
0.25; clomipramine IC50=12.4 0.14 mm.
Potency was determined as independent duplicates for all com-
pounds tested. Serial titrations (10 half log increments) of test
compounds from 30 mm to 1 nm were created in DMSO using the
Janus automated 8 channel pipettor (Perkin–Elmer). A serial titra-
tion of clomipramine was used as a positive control in each assay
plate; BTCP was used as an additional control in some screening
plates. Using a Platemate Plus (Thermofisher Scientific), 500 nL of
each test compound was transferred into assay plates (384 clear
polystyrene plates) along with standard inhibitor and DMSO in the
appropriate control wells. A TryR/DTNB/TrySH mixture (37.5 mLi n
buffer containing 40 mm Hepes and 1 mm Na4EDTA, pH 7.4) was
then added to each well (Platemate Plus, Thermofisher Scientific)
such that final assay concentrations were 3 nm,5 0mm and 6 mm,
respectively. The reaction was started by addition of 4 mL NADPH
(4 mL buffer for LO controls), to yield a final assay concentration
150 mm. The reaction was incubated for 35 min at room tempera-
ture. The absorbance was then measured at 405 8 nm using the
Envision plate reader (Perkin–Elmer).
ActivityBase from IDBS was used for all data processing and analy-
sis. Database querying and report creation was undertaken using
SARgen version 5.4 and SARview version 6.1 from IDBS.
Cell-based assays
Trypanosomes (T. b. brucei, BSF 427 vsg221) were seeded in 96-well
plates at 2000 cells per well in a volume of 200 mL of HMI-9T
[21]
containing 10% FCS. MRC-5 cells were seeded at 2000 cells per
well in a volume of 200 mL of DMEM containing 10% FCS and al-
lowed to adhere for 24 h prior to use.
For compound assessment, compounds were serially diluted in
100% DMSO through a ten-point, one in three dilution curve, in
row orientation using a Janus 8 channel Varispan. This produced a
working stock of 200  final concentration in the assay. Compound
plates contained six test compounds and one standard compound
occupying columns 1–10: row A was omitted from screening due
to potential edge effect and row H contained the standard com-
pound. Each compound working stock (1 mL) was then stamped
into replicate clear 96-well polystyrene assay plates using a Plate-
mate 2 2 (Matrix-Thermofisher) to achieve the final assay concen-
tration at DMSO level of 0.5%.
Assay plates (200 mL final volume per well) were incubated for 69 h
at 378C in an atmosphere of 5% CO2. Resazurin (20 mL of 500 mm)
was then added to each well and the plates incubated for another
4 h. Plates were read for fluorescence at an excitation wavelength
of 528 nm and an emission wavelength of 590 nm.
Mode of inhibition studies
An assay mixture consisting of TryR, NADPH and DTNB was made
up in 40 mm HEPES; 1 mm EDTA (pH 7.4). Aliquots of the assay
mixture (180 mL) containing three different concentrations of test
compound were added to three rows of a microtitre plate, a fourth
row contained only the assay mixture. The test compound concen-
tration ranged from ~0.25 to 1 times the IC50 value. Trypanothione
disulphide was serially diluted across a fifth row of the plate to
produce a 12-point range from 500 mm to 5.8 mm. The
assay was initiated by transferring 20 mL of trypano-
thione disulphide row to each of the assay rows. The
final 200 mL assay contained 150 mm NADPH; 50 mm
DTNB and 20 mUmL
 1 TryR. The linear rate of increase
in absorbance at 412 nm was determined using a Molec-
ular Devices Thermomax plate reader. Each data set was
fitted by nonlinear regression to the Michaelis–Menten
equation using GraFit 5.0 (Erithacus software). The re-
sulting individual fits were examined as Lineweaver–
Burke transformations and the graphs inspected for di-
agnostic inhibition patterns. The entire dataset was then
globally fitted to the appropriate equation (competitive,
mixed or uncompetitive inhibition).
Figure 3. a) The structure of trypanothione (T[S]2), the substrate of TryR. b) The principle
of the DTNB-coupled assay for TryR.
Figure 2. SAR summary for the inhibition of T. brucei TryR by BTCP (1) ana-
logues.
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General: Chemicals and solvents were purchased from the Aldrich
Chemical Company, Fluka, ABCR, VWR, Acros, Fisher Chemicals and
Alfa Aesar and were used as received unless otherwise stated. Air
and moisture sensitive reactions were carried out under an inert at-
mosphere of Ar in oven-dried glassware. Analytical thin-layer chro-
matography (TLC) was performed on precoated TLC plates
(0.20 mm silica gel60 with fluorescent indicator UV254) (Merck).
Plates were air-dried and visualised under a UV lamp (UV254/
365 nm), and where necessary, stained with a solution of ninhydrin
or iodine on silica to aid identification. Flash column chromatogra-
phy was performed using prepacked silica gel cartridges (230–
400 mesh, 40–63 mm) (SiliCycle) using a Teledyne ISCO Combiflash
Companion or Combiflash Retrieve.
1H NMR,
13C NMR, and 2D-NMR
spectra were recorded on a Bruker Avance DPX 500 spectrometer
(
1H at 500.1 MHz,
13C at 125.8 MHz). Chemical shifts (d) are ex-
pressed in ppm recorded using the residual solvent as the internal
reference in all cases. Signal splitting patterns are described as sin-
glet (s), doublet (d), triplet (t), quartet (q), multiplet (m), broad (br),
or a combination thereof. Coupling constants (J) are quoted to the
nearest 0.5 Hz. LC/MS analyses were performed with either an Agi-
lent HPLC 1100 series connected to a Bruker Daltonics MicrOTOF,
or an Agilent Technologies 1200 series HPLC connected to an Agi-
lent Technologies 6130 quadrupole LC/MS; both instruments were
connected to an Agilent diode array detector. LC/MS chromato-
graphic separations were conducted with a Phenomenex Gemini
C18 column, 50 3.0 mm, 5 mm particle size; mobile phase: H2O/
CH3CN+0.1% HCO2H, 80:20!5:95 over 3.5 min, and then held for
1.5 min; flow rate 0.5 mLmin
 1. High resolution electrospray meas-
urements were performed on a Bruker Daltonics MicrOTOF mass
spectrometer.
Procedures for the synthesis of BTCP analogues
Method A (compounds 3, 5, 9–15, 17):
[11] nBuLi (1.6m in hexanes,
4 eq) was added to a solution of the corresponding heteroaromatic
compound (4 eq) in anhyd THF (10 mL) at  788C and stirred for
1 h. The resultant ArLi solution was then added via a cannula to an
ice-cooled solution of the relevant benzotriazoyl adduct prepared
by stirring the corresponding enamine (1 eq) and benzotriazole
(1 eq) in anhyd Et2O (5 mL) for 1 h. The reaction was allowed to
warm to RT and stirred for 16 h. Workup was initiated by the addi-
tion of aq citrate (10% w/v, 20 mL), the layers separated and the
organic layer further extracted with aq citrate (10% w/v, 3 20 mL).
The combined aqueous layers were basified to pH 10 (2m aq
NaOH), extracted into CH2Cl2 (4 50 mL) and the combined CH2Cl2
layers dried (MgSO4), filtered and concentrated in vacuo. The crude
product was purified by flash column chromatography (EtOAc/
Hexane, 0:100!60:40) and if necessary by trituration of the HCl
salts from Et2O.
Method B1 (compounds 4, 6 & 7):
[14] To a suspension of Mg turn-
ings (1 eq) and I2 (2 mg, cat.) in anhyd Et2O (10 mL) was slowly
added a solution of the relevant ArBr (1 eq) in anhyd Et2O (10 mL)
and the mixture refluxed for 2–3 h. To the resultant Grignard solu-
tion was added a solution of nitrile 20 (1 eq) in anhyd Et2O (10 mL)
and the reaction heated at reflux for 16 h. The reaction was
worked up and the products purified as described for method A
above.
Method B2 (compounds 16, & 18):
[15] To a suspension of Mg turn-
ings (27.5 mmol, 669 mg) in anhyd Et2O (25 mL) in a reflux appara-
tus was slowly added a solution of 1,2-dibromoethane (27.5 mmol,
5.17 g) in anhyd Et2O (25 mL) and the resultant mixture allowed to
stir for 3 h. To the resultant MgBr2 solution was added a solution of
benzo[b]thien-2-yl-lithium (27.5 mmol) prepared as outlined in
method A above and the reaction stirred for 30 min at RT. The gen-
erated Grignard solution was then slowly added to the relevant ni-
trile (10 mmol, 2.07 g) in anhyd Et2O (10 mL) and the reaction
heated to reflux for 16 h. The reaction was worked up and the
products purified as described for method A above.
BTCP 1: This was purchased from Tocris Bioscience as the maleate
salt. LCMS analysis confirmed compound identity and that purity
was >95% (diode array).
1-(1-Phenylcyclohexyl)piperidine (PCP) 2: 1-(1-Piperidino)cyclo-
hexene (1 mmol, 165 mg) was added to a suspension of 1H-benzo-
triazole (1 mmol, 119 mg) in anhyd Et2O (5 mL) and stirred at RT for
1 h. The reaction mixture was then cooled to 08C prior to the addi-
tion of phenyllithium (1.8m in dibutylether, 4 mmol, 2.22 mL). The
reaction mixture was allowed to warm to RT and stirred for 16 h.
The reaction was worked up and purified as described for meth-
od A above to give a clear gum (36 mg, 15%), which was further
purified by trituration of the HCl salt from Et2O. The reported anal-
ysis is for the HCl salt.
1H NMR (500 MHz, CD3OD): d=1.20–1.31
(3H, m, CH2CH2CH2 &1   C HH), 1.34–1.43 (1H, m, CHH), 1.63–1.68
(1H, m, CHH), 1.75–1.95 (9H, m, 2 CCHH,1 C HH&3 C H 2), 2.37–
2.44 (2H, m, 2 NCHH), 3.09–3.13 (2H, m, 2 CCHH), 3.76–3.80 (2H,
m, 2 NCHH), 7.55–7.63 (3H, m, 2 m-PhH & p-PhH), 7.70 ppm (2H,
d, J=7.5 Hz, 2 o-PhH).
13C NMR (125 MHz, CD3OD): d=23.1 (CH2),
24.0 (CH2), 24.8 (CH2), 26.2 (CH2), 32.4 (CCH2), 48.9 (NCH2) 72.9 (C),
130.5 (Ph CH), 131.0 (Ph CH), 131.1 (Ph CH), 131.7 ppm (Ph C). MS
(LCMS ES+): m/z (%) 159 (14) [M Piperidine]
+, 244 (100) [M+H]
+.
HRMS (ES+): calcd for C17H26N1 [M+H]
+ 244.2060, found 244.2059
(0.28 ppm).
1-(1-Thiophen-2-yl)cyclohexyl)piperidine 3: Prepared by meth-
od A from thiophene (4 mmol, 337 mg) and 1-(1-piperidino)cyclo-
hexene (1 mmol, 165 mg). The product was obtained as an brown
oil (158 mg, 63%). The reported analysis is for the HCl salt.
1H NMR
(500 MHz, CD3OD): d=1.30–1.45 (4H, m, CH2CH2CH2 &2   C HH),
1.66–1.68 (1H, m, CHH), 1.78–1.81 (1H, m, CHH), 1.88–2.03 (8H, m,
2 CCHH &3 C H 2), 2.55–2.59 (2H, m, 2 NCHH), 2.87–2.89 (2H, m,
2 CCHH), 3.78–3.80 (2H, m, 2 NCHH), 7.27 (1H, dd, J=5.0,
4.0 Hz, thiophene H4), 7.44 (1H, dd, J=4.0, 1.0 Hz, thiophene H3),
7.76 ppm (1H, dd, J=5.0, 1.0 Hz, thiophene H5).
13C NMR
(125 MHz, CD3OD): d=23.1 (CH2), 24.3 (CH2), 24.8 (CH2), 25.6 (CH2),
34.7 (CCH2), 48.85 [under CD3OD, identified by DEPT135 & HSQC]
(NCH2), 71.3 (C), 126.2 (thiophene C4), 130.1 (thiophene C5), 132.5
(thiophene C3), 136.8 ppm (thiophene C2). MS (LCMS ES+): m/z
(%) 165 (50) [M Piperidine]
+, 250 (100) [M+H]
+. HRMS (ES+): calcd
for C15H24N1S1 [M+H]
+ 250.1624, found 250.1622 (0.89 ppm).
1-(1-Biphenyl-4-yl)cyclohexyl)piperidine 4: Prepared by meth-
od B1 from 4-bromobiphenyl (15.5 mmol, 3.65 g). The product was
obtained as a colourless crystalline solid (1.04 g, 21%). The report-
ed analysis is for the free base.
1H NMR (500 MHz, CDCl3): d=1.28–
1.40 (4H, m, 2 CH2CH2CH2), 1.45–1.57 (6H, m, 2 CH2 &2   C HH),
1.73–1.80 (2H, m, 2 CHH), 2.00–2.07 (2H, m, 2 CCHH), 2.16–2.22
(2H, m, 2 CCHH), 2.27–2.39 (2H, m, 2 NCH2), 7.35–7.39 (3H, m,
AA’BB’& p-PhH), 7.47 (2H, t, J=8.0 Hz, 2 m-PhH), 7.60–7.61 (2H, m,
AA’BB’), 7.66 ppm (2H, dd, J=8.0, 1.0 Hz, 2 o-PhH).
13C NMR
(125 MHz, CDCl3): d=22.5 (CH2), 25.0 (CH2), 26.5 (CH2), 27.2 (CH2),
33.7 (CCH2), 46.5 (NCH2), 60.9 (C), 126.05 (biphenyl CH), 127.0 (bi-
phenyl CH), 127.1 (biphenyl CH), 127.8 (biphenyl CH), 128.7 (bi-
phenyl CH), 138.6 (biphenyl C), 139.1 (biphenyl C), 140.9 ppm (bi-
phenyl C). MS (LCMS ES+): m/z (%) 320 (100) [M+H]
+. HRMS (ES+):
calcd for C23H30N1 [M+H]
+ 320.2373, found 320.2375 ( 0.68 ppm).
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Trypanothione Reductase Inhibitors1-(1-Benzo[b]furan-2-yl)cyclohexyl)piperidine 5: Prepared by
method A from benzo[b]furan (4 mmol, 473 mg) and 1-(1-piperidi-
no)cyclohexene (1 mmol, 165 mg). The product was obtained as a
yellow oil (239 mg, 84%). The reported analysis is for the HCl salt.
1H NMR (500 MHz, CD3OD): d=1.31–1.40 (4H, m, CH2CH2CH2 &2  
CHH), 1.69–2.00 (10H, m, 2 CCHH &4 C H 2), 2.66–2.70 (2H, m, 2 
NCHH), 2.99–3.01 (2H, m, 2 CCHH), 3.83–3.85 (2H, m, 2 NCHH),
7.33 (1H, d, J=0.5 Hz, benzo[b]furan H3, 7.35–7.39 (1H, m, ben-
zo[b]furan H), 7.44–7.48 (1H, m, benzo[b]furan H), 7.62 (1H, dd, J=
8.5, 1.0 Hz, benzo[b]furan H), 7.75–7.76 ppm (1H, m, benzo[b]furan
H).
13C NMR (125 MHz, CD3OD): d=22.9 (CH2), 24.4 (CH2), 24.8
(CH2), 25.5 (CH2), 31.9 (CCH2), 49.53 [under CD3OD, identified by
DEPT135 & HSQC] (NCH2), 70.2 (C), 112.6 (benzo[b]furan CH), 112.9
(benzo[b]furan C3), 123.1 (benzo[b]furan CH), 124.9 (benzo[b]furan
CH), 127.2 (benzo[b]furan CH), 128.8 (benzo[b]furan C), 150.4 (ben-
zo[b]furan C), 156.5 ppm (benzo[b]furan C). MS (LCMS ES+): m/z
(%) 199 (82) [M piperidine]
+, 284 (100) [M+H]
+. HRMS (ES+): calcd
for C19H26N1O1 [M+H]
+ 284.2009, found 284.2008 (0.26 ppm).
1-(1-Naphthalen-1-yl)cyclohexyl)piperidine 6: Prepared by meth-
od B1 from 1-bromonaphthalene (10 mmol, 2.07 g). The product
was obtained as a clear oil (316 mg, 11%). The reported analysis is
for the HCl salt. Note, NMR analysis acquired at 508C.
1H NMR
(500 MHz, CD3OD): d=1.12–1.52 (4H, m, 2 CH2CH2CH2), 1.52–1.57
(1H, m, CHH), 1.75–1.80 (1H, m, CHH), 1.86–1.95 (6H, m, 2 CH2 &
2 CHH), 2.18–2.25 (2H, m, 2 CCHH), 2.75–2.84 (2H, m, 2 NCHH),
3.27–3.76 (2H, m, 2 CCHH), 3.82–3.87 (2H, m, 2 NCHH), 7.61 (1H,
dd, J=8.0, 8.0 Hz, naphthyl H), 7.65–7.70 (2H, m, 2 naphthyl H),
8.01 (1H, d, J=7.5 Hz, naphthyl H), 8.06 (1H, dd, J=8.0, 1.0 Hz,
naphthyl H), 8.10 (1H, d, J=8.5 Hz, naphthyl H), 8.62 ppm (1H, d,
J=9.0, naphthyl H).
13C NMR (125 MHz, CDCl3): d=21.6 (CH2), 23.0
(CH2), 23.7 (CH2), 24.7 (CH2), 34.2 (CCH2), 49.1 (NCH2), 76.2 (C), 124.4
(naphthyl CH), 124.7 (naphthyl CH), 125.5 (naphthyl CH), 126.7
(naphthyl C), 127.2 (naphthyl CH), 130.3 (naphthyl CH), 132.1
(naphthyl CH), 132.3 (naphthyl CH), 133.1 (naphthyl C), 135.6 ppm
(naphthyl C). MS (LCMS ES+): m/z (%) 294 (100) [M+H]
+. HRMS
(ES+): calcd for C21H28N2 [M+H]
+ 294.2216, found 294.2225
(2.97 ppm).
1-(1-Naphthalen-2-yl)cyclohexyl)piperidine 7: Prepared by meth-
od B1 from 2-bromonaphthalene (10 mmol, 2.07 g). The product
was obtained as a white crystalline solid (191 mg, 7%). The report-
ed analysis is for the HCl salt.
1H NMR (500 MHz, CD3OD): d=1.19–
1.35 (3H, m, CH2CH2CH2 &C H H), 1.38–1.47 (1H, m, CHH), 1.63–1.67
(1H, m, CHH), 1.72–1.76 (1H, m, CHH), 1.83–1.95 (6H, m, 2 CH2 &
2 CHH), 2.01–2.07 (2H, m, 2 CCHH), 2.43–2.50 (2H, m, 2 CCHH),
3.23–3.28 (2H, m, 2 NCHH), 3.83–3.88 (2H, m, 2 CCHH), 7.61–
7.67 (2H, m, naphthyl H-6 & H-7), 7.78 (1H, dd, J=9.0, 1.5 Hz,
naphthyl H-3), 7.98–7.80 (1H, m, naphthyl H), 8.05–8.06 (1H, m,
naphthyl H), 8.09 (1H, d, J=9.0 Hz, naphthyl H-4), 8.25 ppm (1H, s,
naphthyl H-1).
13C NMR (125 MHz, CD3OD): d=23.1 (CH2), 24.1
(CH2), 24.8 (CH2), 26.2 (CH2), 32.6 (CCH2), 49.0 [under CD3OD, identi-
fied by DEPT135 & HSQC] (NCH2), 73.1 (C), 127.0 (naphthyl C3),
128.0 (naphthyl CH), 128.5 (naphthyl CH), 128.9 (naphthyl CH),
129.1 (naphthyl C), 129.8 (naphthyl CH), 130.1 (naphthyl C4), 131.8
(naphthyl C1), 134.6 (naphthyl C), 134.9 ppm (naphthyl C). MS
(LCMS ES+): m/z (%) 294 (100) [M+H]
+. HRMS (ES+): calcd for
C21H28N2 [M+H]
+ 294.2216, found 294.2220 (1.39 ppm).
1-Methyl-2-(1-piperidin-1-yl)cyclohexyl)-1H-indole 8: Prepared by
a modification of method B2 from 1-methylindole (4 mmol,
525 mg) and nitrile 20 (4 mmol, 768 mg). The product was ob-
tained as a white solid (297 mg, 25%). The reported analysis is for
the free base.
1H NMR (500 MHz, CDCl3): d=.1.18–1.28 (1H, m,
CH2CHHCH2), 1.42–1.57 (8H, m, CH2CH2CH2,2   C H 2 &2   C HH,
1.63–1.71 (3H, m, 3 CHH), 1.83–1.90 (2H, m, 2 CCHH), 2.22–2.27
(2H, m, 2 CCHH), 2.55–2.57 (4H, m, 2 NCH2), 4.09 (3H, s, CH3),
6.52 (1H, s, indole H3), 7.10 (1H, ddd, J=7.5, 7.5, 1.0 Hz, indole
H5), 7.20 (1H, ddd, J=8.0, 7.5, 1.0 Hz, indole H6), 7.32 (1H, d, J=
8.0 Hz, indole H7), 7.57 (1H, d, J=7.5 Hz, indole H-4).
13C NMR
(125 MHz, CDCl3): d=23.8 (CH2), 25.5 (CH2), 26.6 (CH2), 27.3 (CH2),
32.3 (CH3), 46.8 (NCH2), 62.3 (C), 104.6 (indole CH), 108.9 (indole
CH), 119.0 (indole CH), 119.8 (indole CH), 120.8 (indole CH), 127.0
(indole C), 138.7 (indole C), 142.5 ppm (indole C) [Note, two of the
CH2 carbons have an identical chemical shift]. MS (LCMS ES+): m/z
(%) 212 (100) [M piperidine]
+. HRMS (ES+): calcd for C20H29N2
[M+H]
+ 297.2325, found 297.2313 (4.16 ppm).
1-(1-Benzo[b]thiazol-2-yl)cyclohexyl)piperidine 9: Prepared by
method A from benzo[b]thiazole (4 mmol, 541 mg) and 1-(1-piperi-
dino)cyclohexene (1 mmol, 165 mg). The product was obtained as
a yellow semisolid (164 mg, 55%). The reported analysis is for the
free base.
1H NMR (500 MHz, CDCl3): d=1.33–1.37 (2H, m, CH2),
1.44–1.57 (8H, m, 2 CHH &3   C H 2), 1.74–1.81 (2H, m, 2 CHH),
2.07–2.20 (4H, m, 2 CCH2), 2.50–2.57 (4H, m, 2 NCH2), 7.36 (1H,
dd, J=7.5, 7.5 Hz, benzo[b]thiazole H6), 7.45 (1H, dd, J=7.5,
7.5 Hz, benzo[b]thiazole H5), 7.88 (1H, d, J=7.5 Hz, benzo[b]thia-
zole H7), 8.03 ppm (1H, d, J=7.5 Hz, benzo[b]thiazole H4)
13C NMR
(125 MHz, CDCl3): d=22.4 (CH2), 25.0 (CH2), 26.0 (CH2), 27.1 (CH2),
34.7 (CCH2), 46.9 (NCH2), 63.7 (C), 121.4 (benzo[b]thiazole C7), 123.0
(benzo[b]thiazole C4), 124.6 (benzo[b]thiazole C6), 125.5 (benzo[b]-
thiazole C5), 135.0 (benzo[b]thiazole C7a), 152.9 (benzo[b]thiazole
C3a), 176.0 ppm (benzo[b]thiazole C2). MS (LCMS ES+): m/z (%)
301 (100) [M+H]
+. HRMS (ES+): calcd for C18H25N2S1 [M+H]
+
301.1733, found 301.1718 (4.80 ppm).
1-(1-Benzo[b]thiophen-3-yl)cyclohexyl)piperidine 10 & 1-(1-(3-
Bromo-benzo[b]thiophen-2-yl)cyclohexyl)piperidine 11: Prepared
by method A from 3-bromobenzo[b]thiophene (4 mmol, 852 mg)
and 1-(1-piperidino)cyclohexene (1 mmol, 165 mg). The reaction
gave two products that could be separated by column chromatog-
raphy. The reported analysis is for the free bases.
For 10: Rf=0.20 (EtOAc/hexanes, 1:1), clear oil (143 mg, 48%).
1H NMR (500 MHz, CDCl3): d=1.24–1.30 (1H, m, CH2CHHCH2), 1.36–
1.49 (8H, CH2CH2CH2 &C H HCH2CHH), 1.617–1.71 (3H, m,
CH2CHHCH2 &C HHCH2CHH), 1.93–1.99 (2H, m, 2 CCHH), 2.30–2.35
(2H, m, 2 CCHH), 2.52–2.58 (4H, m, 2 NCH2), 7.27 (1H, s, ben-
zo[b]thiophene H2), 7.30–7.33 (2H, m, benzo[b]thiophene H5 &
H6), 7.84–7.87 (1H, m, benzo[b]thiophene H7), 8.55–8.59 ppm (1H,
m, benzo[b]thiophene H4).
13C NMR (125 MHz, CDCl3): d=23.7
(CH2), 25.6 (CH2), 26.7 (CH2), 27.4 (CH2), 30.8 (CCH2), 47.1 (NCH2),
63.5 (C), 122.5 (benzo[b]thiophene C7), 122.7 (benzo[b]thiophene
CH), 123.6 (benzo[b]thiophene CH), 124.2 (benzo[b]thiophene C2),
126.8 (benzo[b]thiophene C4), 138.5 (benzo[b]thiophene C), 140.5
benzo[b]thiophene C), 140.8 ppm (benzo[b]thiophene C). MS
(LCMS ES+): m/z (%) 215 (100) [M piperidine]
+, 300 (34) [M+H]
+.
HRMS (ES+): calcd for C19H26N1S1 [M+H]
+ 300.1780, found 300.1767
(4.50 ppm).
For 11: Rf=0.49 (EtOAc/hexanes, 1:1), clear oil (58 mg, 15%).
1H NMR (500 MHz, CDCl3): d=1.20–1.26 (2H, m, CH2), 1.35–1.49
(8H, m, 3 CH2 &2   C HH), 1.64–1.73 (2H, m, 2 CHH), 1.93–2.00
(2H, m, 2 CCHH), 2.49–2.62 (6H, m, 2 CCHH & 2 NCH2), 7.27–
7.36 (2H, m, benzo[b]thiophene H5 & H6), 7.67 (1H, d, J=8.0 Hz),
benzo[b]thiophene H), 7.80 ppm (1H, d, J=8.0 Hz, benzo[b]thio-
phene H). MS (LCMS ES+): m/z (%) 293 (57) [
79Br M piperidine]
+,
295 (57) [
81Br M piperidine]
+, 378 (100) [
79Br M+H]
+, 380 (100)
[
81Br M+H]
+. HRMS (ES+): calcd for C19H25
79Br1N1S1 [M+H]
+
378.0886, found 378.0897 ( 2.99 ppm).
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MED A. H. Fairlamb et al.1-(1-(5-Bromo-benzo[b]thiophen-2-yl)cyclohexyl)piperidine 12:
Prepared by method A from 5-bromobenzo[b]thiophene (4 mmol,
852 mg) and 1-(1-piperidino)cyclohexene (1 mmol, 165 mg). The
product was obtained as a white solid (43 mg, 11%). The reported
analysis is for the HCl salt.
1H NMR (500 MHz, CD3OD): d=1.31–1.41
(2H, m, 2 CHH), 1.42–1.51 (2H, m, CH2CH2CH2), 1.68–1.73 (1H, m,
CHH), 1.76–1.82 (1H, m, CHH), 1.84–1.93 (2H, m, 2 CHH), 1.95–
2.07 (6H, 2 CH2 &2 C HH), 2.69–2.76 (2H, m, 2 NCHH), 2.91–2.95
(2H, m, 2 CCHH), 3.82–3.87 (2H, m, 2 NCHH), 7.62 (1H, dd, J=
8.5, 2.0 Hz, benzo[b]thiophene H6), 7.75 (1H, s, benzo[b]thiophene
H3), 7.92 (1H, d, J=8.5 Hz, benzo[b]thiophene H7), 8.15 ppm (1H,
d, J=2.0 Hz, benzo[b]thiophene H4).
13C NMR (125 MHz, CDCl3):
d=23.0 (CH2), 24.3 (CH2), 24.9 (CH2), 25.4 (CH2), 34.5 (CCH2), 49.4
(NCH2), 71.4 (C), 120.0 (benzo[b]thiophene C5), 125.1 (benzo[b]thio-
phene C7), 128.3 (benzo[b]thiophene C4), 129.4 (benzo[b]thio-
phene C3), 130.2 (benzo[b]thiophene C6), 139.6 (benzo[b]thio-
phene C), 140.3 (benzo[b]thiophene C), 142.3 ppm (benzo[b]thio-
phene C). MS (LCMS ES+): m/z (%) 293 (70) [
79Br M piperidine]
+,
295 (74) [
81Br M piperidine]
+, 378 (98) [
79Br M+H]
+, 380 (100) [
81Br
M+H]
+. HRMS (ES+): calcd for C19H25
79BrN1S1 [M+H]
+ 378.0886,
found 378.0872 (3.47 ppm).
1-(1-Benzo[b]thiophen-2-yl)cyclohexyl)pyrrolidine 13: Prepared
by method A from benzothiophene (537 mg) and 1-(1-pyrrolidino)-
cyclohexene (151 mg). The product was obtained as an orange
solid (149 mg, 52%). The reported analysis is for the HCl salt.
1H NMR (MHz, CD3OD): d=1.37–1.44 (1H, m, CHH), 1.46–1.55 (2H,
m, 2 CHH), 1.69–1.74 (1H, m, CHH), 1.85–1.99 (6H, m, 2 
NCH2CH2,2  C HH), 2.03–2.09 (2H, m, 2 CCHH), 2.79–2.85 (2H, m,
2 CCHH), 3.37–3.43 (2H, m, 2 NCHH), 3.54–3.59 (2H, m, 2 
NCHH), 7.48–7.52 (2H, m, 2 benzo[b]thiophene H), 7.83 (1H, s,
benzo[b]thiophene H3), 7.96–8.01 ppm (2H, m, 2 benzo[b]thio-
phene H).
13C NMR (125 MHz, CD3OD): d=23.9 (CH2), 25.5 (CH2),
35.8 (CCH2), 49.5 [under CD3OD, identified by DEPT135 & HSQC]
(NCH3), 123.4 (benzo[b]thiophene CH), 125.8 (benzo[b]thiophene
CH), 126.3 (benzo[b]thiophene CH), 127.2 (benzo[b]thiophene C3),
130.1 (benzo[b]thiophene CH), 137.4 (benzo[b]thiophene C), 140.7
(benzo[b]thiophene C), 141.5 ppm (benzo[b]thiophene C). MS
(LCMS ES+): m/z (%) 215 (100) [M pyrrolidine]
+, 286 (41) [M+H]
+.
HRMS (ES+): calcd for C18H24N1S1 [M+H]
+ 286.1624, found 286.1616
(2.74 ppm).
1-(1-Benzo[b]thiophen-2-yl)cyclohexyl)diethylamine 14: Prepared
by method A from benzo[b]thiophene (4 mmol, 537 mg) and 1-(1-
diethylamino)cyclohexene (1 mmol, 153 mg).
[13a] The product was
obtained as a yellow oil (17 mg, 4%). The reported analysis is for
the HCl salt.
1H NMR (500 MHz, CD3OD): d=1.36–1.41 (7H, 2 CH3
&C H 2CHHCH2), 1.46–1.55 (2H, m, 2 CHH), 1.68–1.74 (1H, m,
CH2CHHCH2), 1.93–1.99 (2H, m, 2 CHH), 2.03–2.10 (2H, m, 2 
CCHH), 2.89–3.01 (4H, 2 NCHH&2   C C HH), 3.77–3.85 (2H, m, 2 
NCHH), 7.48–7.52 (2H, m, 2 benzo[b]thiophene H), 7.85 (1H, s,
benzo[b]thiophene H3), 7.95–8.00 ppm (2H, m, 2 benzo[b]thio-
phene H).
13C NMR (125 MHz, CD3OD): d=12.7 (CH3), 24.2 (CH2),
25.4 (CH2), 34.8 (CCH2), 47.2 (NCH2), 73.1 (C), 123.3 (benzo[b]thio-
phene CH), 125.7 (benzo[b]thiophene CH), 126.2 (benzo[b]thio-
phene CH), 127.3 (benzo[b]thiophene CH), 130.3 (benzo[b]thio-
phene C3), 140.6 (benzo[b]thiophene C), 141.5 ppm (benzo[b]thio-
phene C). [Note, one quaternary carbon is missing, or two carbons
have identical shifts]. MS (LCMS ES+): m/z (%) 215 (100) [M die-
thylamine]
+. HRMS (ES+): calcd for C18H26N1S1 [M+H]
+ 288.1780,
found 288.1784 ( 1.24 ppm).
1-(1-Benzo[b]thiophen-2-yl)cyclohexyl)morpholine 15: Prepared
by method A from benzo[b]thiophene (4 mmol, 537 mg) and 1-(1-
morpholino)cyclohexene (1 mmol, 167 mg). The product was ob-
tained as a yellow solid (203 mg, 67%). The reported analysis is for
the HCl salt.
1H NMR (500 MHz, CD3OD): d=1.37–1.43 (1H, m,
CHH), 1.45–1.55 (2H, m, CH2), 1.69–1.74 (1H, m, CHH), 1.96–2.01
(2H, m, 2 CHH), 2.07–2.13 (2H, m, 2 CCHH), 2.88–2.93 (2H, m,
2 CCHH), 2.99–3.05 (2H, m, 2 OCHH), 3.66–3.71 (2H, m, 2 
OCHH), 3.88–3.94 (2H, m, 2 NCHH), 4.04–4.08 (2H, m, 2 NCHH),
7.49–7.53 (2H, m, 2 benzo[b]thiophene H), 7.81 (1H, s, benzo[b]-
thiophene H3), 7.97–8.01 ppm (2H, m, 2 benzo[b]thiophene H).
13C NMR (125 MHz, CD3OD): d=24.3 (CH2), 25.5 (CH2), 34.1 (CCH2),
48.1 (OCH2), 65.2 (NCH2), 72.1 (C), 123.4 (benzo[b]thiophene CH),
125.9 (benzo[b]thiophene CH), 126.3 (benzo[b]thiophene CH),
127.3 (benzo[b]thiophene CH), 130.5 (benzo[b]thiophene C3), 140.7
(benzo[b]thiophene C), 141.7 ppm (benzo[b]thiophene C). MS
(LCMS ES+): m/z (%) 215 (100) [M morpholine]
+, 302 (12) [M+H]
+.
HRMS (ES+): calcd for C18H24N1O1S1 [M+H]
+ 302.1573, found
302.1562 (3.71 ppm).
1-(1-Benzo[b]thiophen-2-yl)cyclohexyl)-4-methylpiperazine 16:
Prepared by method B2 from benzo[b]thiophene (27.5 mmol,
3.69 g) and nitrile 21 (10 mmol, 2.07 g). The product was obtained
as a clear oil (12 mg, 0.4%). The reported analysis is for the free
base.
1H NMR (500 MHz, CDCl3): d=1.44–1.51 (4H, m, cyclohexyl
CH2CH2CH2 &2   C HH), 1.73–1.79 (2H, m, 2 CHH), 2.01–2.14 (4H,
m, 2 CCH2), 2.27 (3H, s, CH3), 2.45–2.67 (8H, 4 piperazine CH2),
7.09 (1H, s, benzo[b]thiophene H3), 7.25–7.32 (2H, m, benzo[b]thio-
phene H5 & H6), 7.70 (1H, dd, J=7.5, 1.0 Hz, benzo[b]thiophene
H7), 7.75–7.76 ppm (1H, m, benzo[b]thiophene H4).
13C NMR
(125 MHz, CDCl3): d=22.4 (CH2), 25.9 (CH2), 35.1 (CCH2), 44.9
(NCH2), 45.6 (CH3), 55.9 (NCH2), 60.7 (C), 121.4 (benzo[b]thiophene
C3), 121.9 (benzo[b]thiophene CH), 123.1 (benzo[b]thiophene CH),
123.7 (benzo[b]thiophene CH), 123.9 (benzo[b]thiophene CH),
139.0 (benzo[b]thiophene C), 139.6 (benzo[b]thiophene C),
147.7 ppm (benzo[b]thiophene C). MS (LCMS ES+): m/z (%) 215
(62) [M piperazine]
+, 315 (100) [M+H]
+. HRMS (ES+) calcd for
C19H27N2S1 [M+H]
+ 315.1889, found 315.1882 (2.46 ppm).
1-(1-Benzo[b]thiophen-2-yl)cyclopentyl)piperidine 17: Prepared
by method A from benzo[b]thiophene (4 mmol, 537 mg) and 1-(1-
piperidino)cyclopentene (1 mmol, 151 mg). The product was ob-
tained as a yellow semisolid (28 mg, 10%). The reported analysis is
for the HCl salt.
1H NMR (500 MHz, CD3OD): d=1.15–1.24 (1H, m,
CH2CHHCH2), 1.55–1.68 (3H, m, 2 CHH&C H 2CHHCH2), 1.80–1.93
(6H, m, 2 CHH&C H2CH2CH2), 2.18–2.24 (2H, m, 2 CCHH), 2.74–
2.85 (4H, m, 2 CCHH&2   N C HH), 3.59–3.64 (2H, m, 2 NCHH),
7.33–7.37, 2H, m, 2 benzo[b]thiophene CH), 7.69 (1H, s, benzo[b]-
thiophene H3), 7.80–7.85 ppm (2H, m, 2 benzo[b]thiophene CH).
13C NMR (125 MHz, CD3OD): d=22.7 (CH2), 22.9 (CH2), 24.6 (CH2),
38.2 (CCH2), 52.3 (NCH2), 77.3 (C), 123.3 (benzo[b]thiophene CH),
125.7 (benzo[b]thiophene CH), 126.2 (benzo[b]thiophene CH),
127.1 (benzo[b]thiophene CH), 130.1 (benzo[b]thiophene C3), 138.0
(benzo[b]thiophene C), 140.8 (benzo[b]thiophene C), 141.6 ppm
(benzo[b]thiophene C). MS (LCMS ES+): m/z (%) 86 (100) [piperi-
dine+H]
+, 201 (82) [M piperidine]
+. HRMS (ES+): calcd for
C18H24N1S1 [M+H]
+ 286.1624, found 286.1619 (1.81 ppm).
4’-Benzo[b]thiophen-2-yl)-1’-methyl-1,4’bipiperidine 18: Prepared
by method B2 from benzo[b]thiophene (27.5 mmol, 3.69 g) and ni-
trile 22 (10 mmol, 2.07 g). The product was obtained as a white
solid (87 mg, 3%). The reported analysis is for the free base.
1H NMR (500 MHz, CDCl3): d=1.30–1.35 (2H, m, CH2CH2CH2), 1.52–
1.57 (4H, m, CH2CH2CH2), 2.23–2.27 (4H, m, 2 CCH2), 2.29 (3H, s,
CH3), 2.36–2.46 (6H, m, 2NCH2 &2   C H 3NCHH), 2.72–2.76 (2H, m,
2 CH 3NCHH), 7.04 (1H, s, benzo[b]thiophene H3), 7.28–7.35 (2H,
m, benzo[b]thiophene H5 & H6), 7.74 (1H, d, J=7.5 Hz, benzo[b]-
thiophene H7), 7.80 ppm (1H, d, J=8.0, benzo[b]thiophene H4).
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Trypanothione Reductase Inhibitors13C NMR (125 MHz, CDCl3): d=24.9 (CH2CH2CH2), 27.0 (CH2CH2CH2),
35.0 (CCH2), 45.8 (CH3), 46.6 (NCH2), 51.9 (CH3NCH2), 58.8 (C), 120.9
(benzo[b]thiophene C3), 122.0 (benzo[b]thiophene C4), 123.2 (ben-
zo[b]thiophene C7), 123.8 (benzo[b]thiophene CH), 124.0 (benzo[b]-
thiophene CH), 138.9 (benzo[b]thiophene C), 139.6 (benzo[b]thio-
phene C), 147.0 ppm (benzo[b]thiophene C). MS (LCMS ES+): m/z
(%) 230 (100) [M piperidine]
+, 315 (9) [M+H]
+. HRMS (ES+): calcd
for C19H27N2S1 [M+H]
+ 315.1889, found 315.1882 (2.35 ppm).
1-(2-Benzo[b]thiophen-2-yl)propan-2-yl)piperidine 19: Prepared
by method A from benzo[b]thiophene (8 mmol, 1.07 g) and 1-
(prop-1-en-2-yl)piperidine
[13b] (2 mmol, 250 mg). The product was
obtained as a yellow oil (79 mg, 15%). The reported analysis is for
the free base.
1H NMR (500 MHz, CDCl3): d=1.41–1.46 (2H, m,
CH2CH2CH2), 1.47 (6H, s, 2 CH3), 1.55–1.59 (4H, m, CH2CH2CH2),
2.48–2.55 (4H, m, 2 NCH2), 7.04 (1H, s, benzo[b]thiophene H3),
7.23–7.31 (2H, m, benzo[b]thiophene H5 & H6), 7.66 (1H, d, J=
7.5 Hz, benzo[b]thiophene H7), 7.78 ppm (1H, d, J=8.0 Hz, ben-
zo[b]thiophene H4).
13C NMR (125 MHz, CDCl3): d=25.0
(CH2CH2CH2), 25.2 (CH3), 26.8 (CH2CH2CH2), 47.7 (NCH2), 59.7 (C),
118.4 (benzo[b]thiophene C3), 122.2 (benzo[b]thiophene C4), 122.8
(benzo[b]thiophene C7), 123.5 (benzo[b]thiophene CH), 123.7 (ben-
zo[b]thiophene CH), 139.8 (benzo[b]thiophene C), 139.9 (benzo[b]-
thiophene C), 158.9 ppm (benzo[b]thiophene C). MS (LCMS ES+):
m/z (%) 175 [M piperidine]
+, 260 [M+H]
+. HRMS (ES+): calcd for
C16H22N1S1 [M+H]
+ 260.1467, found 260.1458 (3.77 ppm).
a-Amino nitriles (20, 21 & 22): Prepared following the a-amino ni-
trile synthesis described in reference [15] and used without further
purification.
Phenyl(1-(piperidin-1-yl)cyclohexyl)methanone 23: To a solution
of nitrile 20 (5 mmol, 960 mg) in anhyd Et2O (25 mL) at  788C was
slowly added phenyllithium (6 mmol, 1.8m solution in dibutylether,
3.33 mL) over 30 min. The reaction was then allowed to warm to
48C and stirred for 16 h. Aq HCl (10%, 20 mL) was then added to
the reaction and the reaction further stirred for 30 min at 08C. The
reaction was then diluted with EtOAc (50 mL), the layers separated
and the organic layer extracted with aq citrate (10%, 2 50 mL).
The combined aqueous layers were basified to pH 10 (NH4OH) and
extracted with CH2Cl2 (4 100 mL). The combined CH2Cl2 layers
were dried (MgSO4), filtered and concentrated in vacuo. The resul-
tant crude product was purified by flash column chromatography
(EtOAc/Hexane, 0:100!2:98) to give a yellow semisolid (237 mg,
17%). The reported analysis is for the HCl salt.
1H NMR (500 MHz,
CD3OD): d=0.95–1.05 (2H, m, cyclohexyl CHHCH2CHH), 1.15–1.24
(1H, m, cyclohexyl CH2CHHCH2), 1.38–1.49 (2H, m, cyclohexyl
CH2CHHCH2 & piperidinyl CH2CHHCH2), 1.64–1.69 (2H, m, cyclohex-
yl CHHCH2CHH), 1.73–1.93 (7H, m, 2 CCHH & piperidinyl
CH2CHHCH2), 2.65–2.70 (2H, m, 2 CCHH), 3.10–3.16 (2H, m, 2 
NCHH), 3.63–3.67 (2H, m, 2 NCHH), 7.47 (2H, t, J=8.0 Hz, 2 m-
PhH), 7.55–7.58 (1H, m, p-PhH), 7.65–7.68 ppm (2H, m, 2 o-PhH).
13C NMR (125 MHz, CD3OD): d=23.0 (CH2), 23.8 (CH2), 24.9 (CH2),
25.3 (CH2), 31.7 (CCH2), 51.1 (NCH2), 77.2 (C), 128.6 (o-Ph CH), 130.2
(m-Ph CH), 133.9 (p-Ph CH), 141.2 (Ph C), 203.6 ppm (CO). MS
(LCMS ES+): m/z (%) 272 (100) [M+H]
+. HRMS (ES+): calcd for
C18H26N1O1 [M+H]
+ 272.2009, found 272.2000 (3.23 ppm).
Benzo[b]thiophen-2-yl(1-(piperidin-1-yl)cyclohexyl)methanone
24: nBuLi (10 mmol, 1.6m in hexanes, 6.25 mL) was added to a so-
lution of benzo[b]thiophene (10 mmol, 1.34 g) in anhyd THF
(25 mL) at  788C and stirred for 1 h. The resultant ArLi solution
was added via a cannula to a solution of nitrile 20 (10 mmol,
1.92 g) in anhyd Et2O (20 mL) at 08C over 15 min and stirred for
5 h. Aq HCl (10%, 20 mL) was then added to the reaction and the
reaction further stirred for 30 min at 08C. The reaction was then di-
luted with EtOAc (50 mL), the layers separated and the organic
layer extracted with aq HCl (1m, 3 25 mL). The combined aque-
ous layers were basified to pH 10 (solid KOH) and extracted with
CH2Cl2 (4 50 mL). The combined CH2Cl2 layers were dried (MgSO4),
filtered and concentrated in vacuo. The resultant crude product
was purified by flash column chromatography (EtOAc/Hexane,
0:100!10:90) to give an off-white foam (414 mg, 13%). The re-
ported analysis is for the free base.
1H NMR (500 MHz, CDCl3): d=
1.08–1.17 (1H, m, CHH), 1.49–1.73 (13H, m, CHH, 5 CH2 &2  
CCHH), 2.16–2.21 (2H, m, 2 CCHH), 2.64–2.68 (4H, m, 2 NCH2),
7.37 (1H, ddd, J=8.0, 7.0, 1.0 Hz, benzo[b]thiophene H6), 7.43 (1H,
ddd, J=8.0, 7.0, 1.0 Hz, benzo[b]thiophene H5), 7.83–7.88 (2H, m,
benzo[b]thiophene H4 & H7), 8.25 ppm (1H, d, J=0.5 Hz, benzo[b]-
thiophene H3).
13C NMR (125 MHz, CDCl3): d=23.2 (CH2), 25.2 (CH2),
26.0 (CH2), 26.2 (CH2), 29.7 (CCH2), 47.6 (NCH2), 70.1 (C), 122.4 (ben-
zo[b]thiophene C4), 124.4 (benzo[b]thiophene C6), 125.4 (benzo[b]-
thiophene C7), 126.7 (benzo[b]thiophene C5), 130.7 (benzo[b]thio-
phene C3), 138.0 (benzo[b]thiophene C), 138.9 (benzo[b]thiophene
C), 143.3 (benzo[b]thiophene C), 199.1 ppm (CO). MS (LCMS ES+):
m/z (%) 328 (100) [M+H]
+. HRMS (ES+): calcd for C20H26N1O1S1
[M+H]
+ 328.1730, found 328.1724 (1.77 ppm).
Diphenyl(1-(piperidin-1-yl)cyclohexyl)methanol 25: To a solution
of ketone 20 (1 mmol, 271 mg) in anhyd Et2O (10 mL) at 08C was
added phenyllithium (1 mmol, 1.8m solution in dibutylether,
556 mL) and the reaction allowed to warm to 258C and stirred for
2.5 h. Workup was initiated by the addition of saturated aq NH4Cl
(10 mL), the layers were separated and the aqueous phase further
extracted with Et2O (3 10 mL), the combined organics were dried
(MgSO4), filtered and concentrated in vacuo. The resultant crude
product was purified by flash column chromatography (EtOAc/
Hexane, 0:100!1:99) to give a white solid (239 mg, 68%). The re-
ported analysis is for the HCl salt.
1H NMR (500 MHz, CD3OD): d=
1.28–1.36 (1H, m, CH2CHHCH2), 1.43–1.93 (11H, m, 5 CH2 &
CH2CHHCH2), 2.21–2.29 (2H, m, 2 CCHH), 2.52–2.58 (2H, m, 2 
CCHH), 3.07–3.19 (4H, m, 2 NCH2), 7.41 (2H, t, J=7.5 Hz, 2 
p-PhH), 7.49 (4H, dd, J=7.5, 7.5 Hz, 4 m-PhH), 7.95 ppm (4H, d, J=
7.5 Hz, 4 o-PhH).
13C NMR (125 MHz, CD3OD): d=22.7 (CH2), 23.5
(CH2), 25.2 (CH2), 27.0 (CH2), 29.7 (CCH2), 54.7 (NCH2), 80.6 (C), 83.0
(C), 128.8 (o-Ph CH), 129.5 (p-Ph CH), 129.7 (m-Ph CH), 143.5 ppm
(Ph C). MS (LCMS ES+): m/z (%) 350 (100) [M+H]
+. HRMS (ES+):
calcd for C24H32N1O1 [M+H]
+ 350.2478, found 350.2481 (0.83 ppm).
tert-Butyl 4’-cyano-1,4’-bipiperidine-1’-carboxylate 26: To a sus-
pension of MgSO4 (126 mmol, 15.2 g) in anhyd DMF (6 mL) was
added 1-Boc-4-piperidone (26 mmol, 5.18 g), piperidine (40 mmol,
3.41 g) and acetone cyanohydrin (26 mmol, 2.21 g). The reaction
mixture was then heated to 508C for 4 d. The reaction mixture was
then poured into ice water (100 mL) and stirred for 30 min before
extraction with Et2O (4 100 mL). The combined Et2O layers were
washed with water (5 500 mL), dried (MgSO4), filtered and con-
centrated in vacuo to give a cream solid that was used without fur-
ther purification (6.53 g, 86%). The reported analysis is for the free
base.
1H NMR (500 MHz, CDCl3): d=1.47 (9H, s, tBu), 1.49–1.53 (2H,
m, CH2CH2CH2), 1.61–1.72 (6H, m, CH2CH2CH2 &2   C C HH), 2.11–
2.16 (2H, m, 2 CCHH), 2.56–2.64 (4H, m, 2 NCH2), 3.12–3.21 (2H,
m, 2 NBocCHH), 3.89–4.06 ppm (2H, m, 2 NBocCHH).
13C NMR
(125 MHz, CDCl3): d=24.1 (CH2CH2CH2), 26.1 (CH2CH2CH2), 28.4 (tBu
CH3), 33.6 (CCH2) [broad peak due to restricted flexibility of the
ring system], 39.6 & 40.4 (BocNCH2) [two peaks due to restricted
flexibility of the ring system], 47.7 (NCH2), 60.5 (C), 80.0 (tBu C),
118.3 (CN), 154.4 ppm (CO). MS (LCMS ES+): m/z (%) 211 (20)
[M tBu CN+H]
+, 238 (64) [M tBu+H]
+, 267 (18) [M CN]
+, 294
(100) [M+H]
+. HRMS (ES+): calcd for C16H28N3O2 [M+H]
+ 294.2176,
found 294.2181 ( 1.55 ppm).
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ylate 27: Prepared by method B2 from benzo[b]thiophene
(55 mmol, 7.38 g) and nitrile 26 (20 mmol, 5.87 g). The product was
obtained as a white solid (465 mg, 6%). The reported analysis is for
the free base.
1H NMR (500 MHz, CDCl3): d=1.31–1.35 (2H, m,
CH2CH2CH2), 1.47 (9H, s, tBu), 1.53–1.58 (4H, m, CH2CH2CH2), 2.06–
2.13 (2H, m, 2 CCHH), 2.16–2.22 (2H, m, 2 CCHH), 2.41–2.45 (4H,
m, 2 NCH2), 3.39–3.44 (2H, m, 2 NBocCHH), 3.63–3.68 (2H, m, 2 
NBocCHH), 7.05 (1H, s, benzo[b]thiophene H3), 7.29–7.36 (2H, m,
benzo[b]thiophene H5 & H6), 7.75 (1H, d, J=7.5 Hz, benzo[b]thio-
phene H7), 7.81 ppm (1H, d, J=7.5 Hz, benzo[b]thiophene H4).
13C NMR (125 MHz, CDCl3): d=24.8 (CH2CH2CH2), 26.9 (CH2CH2CH2),
28.5 (tBu CH3), 34.9 & 35.2 (CCH2) [two peaks due to restricted flexi-
bility of the ring system], 39.5 & 40.5 (BocNCH2) [two peaks due to
restricted flexibility of the ring system], 46.7 (NCH2), 59.3 (C), 79.4
(tBu C), 120.8 (benzo[b]thiophene C3), 122.0 (benzo[b]thiophene
C4), 123.3 (benzo[b]thiophene C7), 123.9 (benzo[b]thiophene CH),
124.1 (benzo[b]thiophene CH), 138.8 (benzo[b]thiophene C), 139.5
(benzo[b]thiophene C), 146.1 (benzo[b]thiophene C), 154.9 ppm
(CO). MS (LCMS ES+): m/z (%) 260 (100) [M piperidine tBu]
+, 423
(16) [M+Na]
+. HRMS (ES+): calcd for C23H33N2O2S1 [M+H]
+
401.2257, found 401.2257 (0.10 ppm).
4’-(Benzo[b]thiophen-2-yl)-[1,4’]bipiperidine 28: To a solution of
27 (0.43 mmol, 174 mg) in anhyd CH2Cl2 (10 mL) at 08C was added
TFA (1 mL) and the reaction mixture stirred for 1 h, before being
poured into aq NaOH (2m, 10 mL). The resultant biphasic mixture
was separated and the aqueous layer extracted with CH2Cl2 (3 
10 mL), the CH2Cl2 layers were then combined, dried (MgSO4), fil-
tered and concentrated in vacuo. The crude product was purified
by flash column chromatography (CH3OH/CH2Cl2, 0:100!10:90) to
give an off-white foam (75 mg, 58%). The reported analysis is for
the free base.
1H NMR (500 MHz, CDCl3): d=1.28–1.34 (2H, m,
CH2CH2CH2), 1.52–1.56 (4H, m, CH2CH2CH2), 2.19–2.26 (4H, m, 2 
CCH2), 2.37–2.43 (4H, m, 2 NCH2), 2.89–2.93 (2H, m, 2 NHCHH),
3.19–3.24 (2H, m, 2 NHCHH), 7.03 (1H, s, benzo[b]thiophene H3),
7.28–7.35 (2H, m, benzo[b]thiophene H5 & H6), 7.74 (1H, d, J=
7.5 Hz, benzo[b]thiophene H7), 7.79 ppm (1H, d, J=8.0 Hz, ben-
zo[b]thiophene H4).
13C NMR (125 MHz, CDCl3): d=24.7
(CH2CH2CH2), 26.8 (CH2CH2CH2), 34.8 (CCH2), 41.5 (NHCH2), 46.3
(NCH2), 58.9 (C), 120.8 (benzo[b]thiophene C3), 121.9 (benzo[b]thio-
phene C4), 123.2 (benzo[b]thiophene C7), 123.9 (benzo[b]thio-
phene CH), 124.1 (benzo[b]thiophene CH), 138.6 (benzo[b]thio-
phene C), 139.3 (benzo[b]thiophene C), 145.9 ppm (benzo[b]thio-
phene C). MS (LCMS ES+): m/z (%) 171.5 (70) [M+MeCN+2H]
2+,
216 (100) [M piperidine]
+, 301 (20) [M+H]
+.
General acylation procedure for the synthesis of analogues 29–
32: TFA (1 mL) was added to a solution of 27 (0.125 or 0.25 mmol,
50 or 100 mg) in anhyd CH2Cl2 (9 mL), at 08C and stirred for 2 h
before the reaction was concentrated in vacuo. The resultant crude
secondary amine 28 was redissolved in anhyd pyridine (5 mL),
before the addition of cat DMAP (1 mg) and the relevant acid chlo-
ride (4 eq) and the reaction mixture stirred at RT for 16 h. The reac-
tion was concentrated in vacuo and the crude mixture partitioned
between CH2Cl2 (5 mL) and aq NaOH (2m, 5 mL) and further
worked up and purified as described for 28 above.
1-(4’-Benzo[b]thiophen-2-yl)-1,4’-bipiperidin-1’-yl)ethanone 29:
Prepared following the general acylation procedure using AcCl
(1 mmol, 78.5 mg) to give a brown glass (58 mg, 68%). The report-
ed analysis is for the HCl salt.
1H NMR (500 MHz, CD3OD): d=1.29–
1.39 (1H, m, CH2CHHCH2), 1.75–1.90 (3H, m, CHHCHHCHH), 1.97–
2.03 (2H, m CHHCH2CHH), 2.05–2.12 (1H, m, CHH), 2.15 (3H, s,
CH3), 2.17–2.24 (1H, m, CHH), 2.63–2.70 (1H, m, CHH), 2.73–2.82
(2H, m, 2 CHH), 2.97–3.03 (2H, m, 2 CHH), 3.15–3.22 (1H, m,
CHH), 3.81–3.87 (2H, m, 2 CHH), 4.13–4.18 (1H, m, CHH), 4.72–
4.78 (1H, m, CHH), 7.49–7.54 (2H, m, 2 benzo[b]thiophene H),
7.88 (1H, s, benzo[b]thiophene H3), 7.97–8.02 ppm (2H, m, 2 ben-
zo[b]thiophene H). MS (LCMS ES+): m/z (%) 258 (44) [M piperi-
dine]
+, 343 (100) [M+H]
+. HRMS (ES+): calcd for C20H27N2O1S1
[M+H]
+ 343.1839, found 343.1836 (0.63 ppm).
ACHTUNGTRENNUNG(4’-ACHTUNGTRENNUNG(Benzo[b]thiophen-2-yl)-1,4’-bipiperidinyl-1’-yl)ACHTUNGTRENNUNG(phenyl)-
ACHTUNGTRENNUNGmethanone 30: Prepared following the general acylation proce-
dure using benzoyl chloride (1 mmol, 141 mg) to give a brown
glass (77 mg, 76%). The reported analysis is for the HCl salt. Note,
peaks are broad and poorly defined, possibly due to rotamers, or
restricted flexibility in the aliphatic ring systems.
1H NMR (500 MHz,
CD3OD): d=1.27–1.41 (1H, m, CH2CHHCH2), 1.71–2.01 (5H, m,
CH2CHHCH2), 2.13–2.32 (2H, m, 2 CHH), 2.65–3.17 (6H, m, 2 CH2,
&2   C HH), 3.67–4.04 (3H, m, 3 CHH), 4.77–4.89 (1H, m, CHH),
7.45–7.56 (7H, m, 5 PhH & 2 benzo[b]thiophene H), 7.87 (1H, s,
benzo[b]thiophene H3), 7.97–8.02 ppm (2H, m, 2 benzo[b]thio-
phene H). MS (LCMS ES+): m/z (%) 320 (70) [M-piperidine]
+, 405
(100) [M+H]
+ HRMS (ES+): calcd for C25H29N2O1S1 [M+H]
+ 405.1995,
found 405.1981 (3.44 ppm).
1-(4’-(Benzo[b]thiophen-2-yl)-1,4’-bipiperidinyl-1’-yl)-2-phenyl-
ACHTUNGTRENNUNGethanone 31: Prepared following the general acylation procedure
using phenylacetyl chloride (0.5 mmol, 77 mg) to give a clear glass
(40 mg, 76%). The reported analysis is for the HCl salt.
1H NMR
(500 MHz, CD3OD): d=1.27–1.37 (1H, m, CH2CHHCH2), 1.72–2.04
(7H, m, CH2CHHCH2 &2   C HH), 2.67–2.78 (3H, m, 3 CHH), 2.90–
2.96 (1H, m, CHH), 2.98–3.04 (1H, m, CHH), 3.10–3.17 (1H, m, CHH),
3.73–3.90 (4H, m, 2 CHH & COCH2Ph), 4.25–4.31 (1H, m, CHH),
4.77–4.83 (1H, m, CHH), 7.27–7.32 (3H, m, 2 o-PhH & p-PhH),
7.35–7.39 (2H, m, 2 m-PhH), 7.49–7.54 (2H, m, 2 benzo[b]thio-
phene CH), 7.85 (1H, s, benzo[b]thiophene H3), 7.96–8.02 ppm
(2H, m, 2 benzo[b]thiophene CH). MS (LCMS ES+): m/z (%) 419
(100) [M+H]
+. HRMS (ES+): calcd for C26H31N2O1S1 [M+H]
+
419.2152, found 419.2140 (2.67 ppm).
1-(4’-(Benzo[b]thiophen-2-yl)-1,4’-bipiperidinyl-1’-yl)-2-(dimethyl-
ACHTUNGTRENNUNGamino)ethanone 32: Prepared following the general acylation pro-
cedure using dimethylaminoacetyl chloride hydrochloride (1 mmol,
158 mg) to give an orange glass (27 mg, 28%). The reported analy-
sis is for the HCl salt.
1H NMR (500 MHz, CD3OD): d=1.29–1.38 (1H,
m, CH2CHHCH2), 1.75–1.80 (1H, m, CH2CHHCH2), 1.95–2.02 (4H, m,
CH2CH2CH2), 2.32–2.38 (1H, CHH, m,), 2.47–2.54 (1H, m, CHH), 2.74–
2.80 (3H, m, 2 NCHH&C HH), 2.93 (3H, s, CH3), 2.98–3.05 (5H, m,
CH3 &2   C HH), 3.14–3.21 (1H, m, CHH), 3.82–3.94 (3H, m, 2 
NCHH&C HH), 4.22 (1H, d, J=16.0 Hz, COCHH), 4.49 (1H, d, J=
16.0 Hz, COCHH), 4.71–4.76 (1H, m, CHH), 7.49–7.54 (2H, m, 2 
benzo[b]thiophene CH), 7.90 (1H, s, benzo[b]thiophene H3), 7.97–
8.02 ppm (2H, m, 2 benzo[b]thiophene CH). MS (LCMS ES+): m/z
(%) 151 (41) [M+H piperidine]
2+, 193.5 (17) [M+2H]
2+, 301 (100)
[M piperidine]
+, 386 (7) [M+H]
+. HRMS (ES+): calcd for
C22H32N3O1S1 [M+H]
+ 386.2261, found 386.2270 ( 2.45 ppm).
4-(2-(4’-(Benzo[b]thiophen-2-yl)-1,4’-bipiperidin-1’-yl)ethyl)mor-
pholine 33: TFA (1 mL) was added to a solution of 27 (0.25 mmol,
100 mg) in anhyd CH2Cl2 (10 mL), at 08C and stirred for 1.5 h
before being poured into aq NaOH (2m, 10 mL). The resultant bi-
phasic mixture was separated and the aqueous layer extracted
with CH2Cl2 (3 10 mL), the CH2Cl2 layers were then combined,
dried (MgSO4), filtered and concentrated in vacuo. The resultant
crude secondary amine 28 was redissolved in anhyd CH3CN (5 mL),
before the addition of K2CO3 (0.375 mmol, 52 mg) and 4-(2-chloroe-
thyl)morpholine hydrochloride (0.5 mmol, 93 mg) and the reaction
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the reaction mixture adsorbed directly onto silica and purified as
described for 28 to give a clear glass (16 mg, 15%). The reported
analysis is for the HCl salt. Note, peaks are broad and poorly de-
fined making assignment of the spectra difficult.
1H NMR (500 MHz,
CD3OD): d=1.32–1.41 (1H, m, CHH), 1.76–1.82 (1H, m, CHH), 1.89–
2.05 (4H, m), 2.77–2.88 (4H, m), 2.77–2.88 (4H, m), 2.99–3.11 (2H,
m), 3.21–3.68 (10H, m) [Note, overlaps solvent peak], 3.83–4.03
(8H, m), 7.51–7.57 (2H, m, 2 benzo[b]thiophene H), 7.94 (1H, s,
benzo[b]thiophene H3), 7.98–8.04 ppm (2H, m, 2 benzo[b]thio-
phene H). MS (LCMS ES+): m/z (%) 207 (68) [M+2H]
2+, 329 (26)
[M piperidine]
+, 414 (100) [M+H]
+. HRMS (ES+): calcd for
C24H36N3O1S1 [M+H]
+ 414.2574, found 414.2579 ( 1.23 ppm).
4’-(Benzo[b]thiophen-2-yl)-1’-benzyl-1,4’-bipiperidine 34: LiAlH4
(0.29 mmol, 2.0m in THF, 143 mL) was added to a solution of 30
(0.095 mmol, 39 mg) in anhyd THF (3 mL) and the reaction heated
at 408C for 3 h before the reaction was quenched by the careful
addition of aq HCl (10%, 5 mL). The aqueous phase was then ad-
justed to pH 10 by the addition of aq NaOH (2m) and extracted
with EtOAc (3 10 mL). The combined EtOAc layers were dried
(MgSO4), filtered and concentrated in vacuo. The crude product
was purified by flash column chromatography (CH3OH/CH2Cl2,
0:100!10:90+1% NH4OH) to give a clear glass (6 mg, 15%). The
reported analysis is for the HCl salt.
1H NMR (500 MHz, CD3OD): d=
1.30–1.37 (1H, m, CH2CHHCH2), 1.75–1.82 (1H, m, CH2CHHCH2),
1.95–2.02 (4H, m, CH2CH2CH2), 2.77–2.84 (4H, m, 2 CH2), 3.09–3.23
(4H, m, 2 CH2), 3.68–3.73 (2H, m, 2 CHH), 3.79–3.85 (2H, m, 2 
CHH), 4.28 (2H, s, CH2Ph), 7.48–7.57 (7H, m, 5 PhH & 2 benzo[b]-
thiophene H), 7.91 (1H, s, benzo[b]thiophene H3), 8.00–8.04 ppm
(2H, m, 2 benzo[b]thiophene H). MS (LCMS ES+): m/z (%) 196 (86)
[M+2H]
2+, 306 (100) [M piperidine]
+, 391 (38) [M+H]
+. HRMS
(ES+): calcd for C25H31N2S1 [M+H]
+ 391.2202, found 391.2197
(1.50 ppm).
2-(4’-(Benzo[b]thiophen-2-yl)-1,4’-bipiperidinyl-1’-yl)-N,N-dime-
thylethanamine 35: LiAlH4 (0.21 mmol, 2.0m in THF, 105 mL) was
added to a solution of 32 (0.07 mmol, 27 mg) in anhyd THF
(0.5 mL) and the reaction heated at 408C for 30 min, before the re-
action was quenched by the careful addition of water. The aque-
ous phase was then adjusted to pH 10 by the addition of aq NaOH
(2m) and the aqueous phase extracted with CH2Cl2 (3 10 mL), the
combined CH2Cl2 layers were dried (MgSO4), filtered and concen-
trated in vacuo. The crude product was purified by flash column
chromatography (CH3OH/CH2Cl2, 0:100!10:90+1% NH4OH) to
give a white solid (11 mg, 42%). The reported analysis is for the
HCl salt. Note, peaks are broad and poorly defined making assign-
ment of the spectra difficult.
1H NMR (500 MHz, CD3OD): d=1.31–
1.39 (1H, m, CHH), 1.76–1.82 (1H, m, CHH), 1.92–2.03 (4H, m),
2.74–2.85 (4H, m), 2.98 (6H, s, 2 CH3), 3.11–3.24 (3H, m), 3.42–
3.80 (7H, m), 3.83–4.89 (2H, m), 7.51–7.55 (2H, m, 2 benzo[b]thio-
phene H), 7.91 (1H, s, benzo[b]thiophene H3), 7.99–8.03 ppm (2H,
m, 2 benzo[b]thiophene H). MS (LCMS ES+): m/z (%) 186 (100)
[M+2H]
2+, 287 (24) [M piperidine]
+, 372 (39) [M+H]
+. HRMS (ES+):
calcd for C22H34N3S1 [M+H]
+ 372.2468, found 372.2464 (1.11 ppm).
cis-&trans-1-(Benzo[b]thiophen-2-yl)-4-tert-butylcyclohexanol
36: A solution of nBuLi (40 mmol, 1.6m in hexanes, 25 mL) was
added to a solution benzo[b]thiophene (40 mmol, 5.37 g) in anhyd
THF (100 mL) at  788C and stirred for 2 h. The ArLi solution was
then added via a cannula to a suspension of CeCl3 (40 mmol, pre-
pared by heating 14.9 g CeCl3.7H2O at 1508C for 6 h under
vacuum) in THF (50 mL) at  788C for 30 min. A solution if 4-tert-
butylcyclohexanone (36 mmol, 5.55 g) in anhyd THF (20 mL) was
added to the arylcerium solution and the reaction allowed to
warm to 258C and stirred for 16 h. The workup was initiated by
the addition of saturated aq NH4Cl (100 mL), the layers were sepa-
rated and the aqueous phase extracted with CH2Cl2 (3 100 mL).
The combined organics were dried (MgSO4), filtered and concen-
trated in vacuo. The resultant cream solid was purified by flash
column chromatography (EtOAc/Hexane, 0:100!10:90) to give a
mixture of cis and trans isomers as a white solid (7.56 g, 73%).
Note, a small aliquot of the product was further purified to sepa-
rate the isomers for analytical purposes. Note, the assignment of
the isomers as cis,o rtrans is made by comparison of the shifts of
the tert-butyl peaks in the
1H NMR spectra as compared to those
published for 1-phenyl-4-tert-butyl-cyclohexanol.
[22]
For cis-36: Rf=0.34 (EtOAc/hexanes, 1:9).
1H NMR (500 MHz,
CDCl3): d=0.93 (9H, s, tBu), 1.10–1.16 (1H, m, CH), 1.51–1.60 (2H,
m, 2 CHCHH), 1.72–1.77 (2H, m, 2 CHCHH), 1.86–1.94 (2H, m, 2 
CCHH), 2.10–2.15 (2H, m 2 CCHH), 7.19 (1H, s, benzo[b]thiophene
H-3), 7.27–7.35 (2H, m, benzo[b]thiophene H5 & H6), 7.71 (1H, d,
J=8.0 Hz, benzo[b]thiophene H-7), 7.81 ppm (1H, d, J=8.0 Hz,
benzo[b]thiophene H-4).
13C NMR (125 MHz, CDCl3): d=22.8
(CHCH2), 27.6 (CH3), 32.5 (tBu C), 40.2 (CCH2), 47.4 (CH), 72.1 (COH),
117.9 (benzo[b]thiophene C3), 122.4 (benzo[b]thiophene C4), 123.3
(benzo[b]thiophene C7), 123.9 (benzo[b]thiophene CH), 124.2 (ben-
zo[b]thiophene CH), 139.0 (benzo[b]thiophene C), 139.9 (benzo[b]-
thiophene C), 155.9 ppm (benzo[b]thiophene C). MS (LCMS ES+):
m/z (%) 271 (100) [M OH]
+, 599 (12) [2M+Na]
+.
For trans-36: Rf=0.16 (EtOAc/hexanes, 1:9).
1H NMR (500 MHz,
CDCl3): d=0.81 (9H, s, tBu), 1.15–1.25 (3H, m, CH & 2 CHCHH),
1.82–1.91 (4H, m, 2 CHCHH&2   C C HH), 2.49–2.53 (2H, m, 2 
CCHH), 7.32–7.39 (3H, m, benzo[b]thiophene H-3, H-5 & H-6), 7.76–
7.77 (1H, m, benzo[b]thiophene H-7), 7.85 ppm (1H, d, J=7.5 Hz,
benzo[b]thiophene H-4).
13C NMR (125 MHz, CDCl3): d=25.0
(CHCH2), 27.6 (CH3), 32.3 (tBu C), 40.0 (CCH2), 47.6 (CH), 72.7 (COH),
121.0 (benzo[b]thiophene C3), 122.4 (benzo[b]thiophene C4), 123.6
(benzo[b]thiophene C7), 124.2 (benzo[b]thiophene CH), 124.4 (ben-
zo[b]thiophene CH), 139.5 (benzo[b]thiophene C), 139.9 (benzo[b]-
thiophene C), 151.2 ppm (benzo[b]thiophene C). MS (LCMS ES+):
m/z (%) 271 (100) [M OH]
+.
1-(Benzo[b]thiophen-2-yl)-4-tert-butylcyclohexanamine 37: NaN3
(20 mmol, 1.30 g) was carefully added to a solution of TCA
(10 mmol, 1.63 g) in CHCl3 (50 mL) at  208C. After stirring for
15 min a solution of cis/trans-36 (6.5 mmol, 1.87 g) in CHCl3
(200 mL) was added drop-wise and the reaction allowed to warm
to 08C and stirred for a further 30 min. Workup was initiated by
pouring the reaction into water (200 mL) followed by adjusting the
aqueous layer to pH 9 (aq NH4OH), before the layers were separat-
ed and the aqueous phase extracted with CHCl3 (3 200 mL), the
CHCl3 layers were combined, dried (MgSO4), filtered and concen-
trated in vacuo to give a mixture of the cis/trans-azide contaminat-
ed with olefin elimination product, which was further reacted with-
out purification. A solution of LiAlH4 (20 mmol, 1.0m in THF, 20 mL)
was added to a solution of the crude azide in anhyd Et2O (20 mL)
in a reflux apparatus and the reaction stirred at 258C for 2 h
before the reaction was quenched by the addition of water
(20 mL) followed by aq NaOH (2m, 20 mL). Subsequently the bi-
phasic mixture was filtered through Celite, the Celite washed with
THF (20 mL), the layers separated and the aqueous phase extracted
with Et2O (2 40 mL) and the organics combined and concentrated
in vacuo. The resultant crude mixture was partitioned between
Et2O (100 mL) and aq citrate (10%, 100 mL) and further worked up
as described in method A above to give a white solid (84 mg, 2%
over two steps), which was used without further purification. MS
(LCMS ES+): m/z (%) 271 (100) [M NH2]
+.
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38: To a suspension of amine 37 (0.3 mmol, 84 mg) and K2CO3
(1.35 mmol, 186 mg) in anhyd CH3CN (10 mL) was added 1,5-dibro-
mopentane (0.66 mmol, 152 mg). The subsequent reaction mixture
was heated at reflux for 84 h, filtered and concentrated in vacuo.
The resultant crude product was partitioned between H2O and
Et2O (1:2, 75 mL), the layers separated and the aqueous phase ex-
tracted with Et2O (2 50 mL). The combined Et2O layers were then
extracted with aq citrate (10%, 3 100 mL), the combined aqueous
layers were then basified to pH 10 (aq NH4OH) and subsequently
extracted with EtOAc (3 100 mL). The combined EtOAc layers
were dried (MgSO4), filtered and concentrated in vacuo. The crude
product was purified by flash column chromatography (EtOAc/
Hexane, 0:100!50:50) to give cis- and trans-38, the latter of which
was further purified by trituration of the HCl salt from Et2O.
For cis-38: Rf=0.77 (EtOAc/hexanes, 1:9). The reported analysis is
for the free base. Note, 1H NMR analysis was performed at 508C
due to broad peaks.
1H NMR (500 MHz, CDCl3): d=0.84 (9H, s, tBu
CH3), 1.03–1.09 (1H, m, CH), 1.23–1.28 (2H, m, 2 CHH), 1.44–1.57
(10H, m, 2 CHH, 3 CH2 & 2 CCHH), 2.33–2.38 (4H, m, 2 NCH2),
2.47–2.51 (2H, m, 2 CCHH), 6.93 (1H, s, benzo[b]thiophene H3),
7.14–7.23 (2H, m, benzo[b]thiophene H5 & H6), 7.62 (1H, d, J=
8.0 Hz, benzo[b]thiophene H), 7.69 ppm (1H, d, J=8.0 Hz, ben-
zo[b]thiophene H).
13C NMR (125 MHz, CDCl3): d=21.9 (CH2), 25.0
(CH2), 27.3 (CH2), 27.6 (CH3), 32.6 (tBu C), 36.1 (CCH2), 46.2 (NCH2),
47.7 (CH), 58.8 (C), 119.1 (benzo[b]thiophene CH), 122.0 (benzo[b]-
thiophene CH), 123.1 (benzo[b]thiophene CH), 123.4 (benzo[b]thio-
phene CH), 123.9 (benzo[b]thiophene CH), 138.5 (benzo[b]thio-
phene C), 139.6 (benzo[b]thiophene C), 149.9 ppm (benzo[b]thio-
phene C). MS (LCMS ES+): m/z (%) 271 (100) [M piperidine]
+, 356
(92) [M+H]
+. HRMS (ES+): calcd for C23H34N1S1 [M+H]
+ 356.2406,
found 356.2405 (0.49 ppm).
For trans-38: Rf=0.08 (EtOAc/hexanes, 1:9). The reported analysis
is for the HCl salt.
1H NMR (500 MHz, CD3OD): d=0.68 (9H, s, tBu
CH3), 1.09–1.24 (4H, m, 2 CHH &C H 2), 1.62–1.76 (3H, m, 2 CHH
& CH), 1.83–1.92 (6H, m, & 4 CHH & 2 CCHH), 2.57–2.63 (2H, m,
2 NCHH), 2.86–2.90 (2H, m, 2 CCHH), 3.69–3.74 (2H, m, 2 
NCHH), 7.35–7.38 (2H, m, 2 benzo[b]thiophene H), 7.65 (1H, s,
benzo[b]thiophene H3), 7.81–7.87 ppm (2H, m, 2 benzo[b]thio-
phene H).
13C NMR (125 MHz, CD3OD): d=22.9 (CH2), 24.9 (CH2),
25.4 (CH2), 27.7 (CH2), 32.9 (C), 35.0 (CCH2), 47.8 (CH), 49.4 [under
CD3OD, identified by DEPT135 & HSQC] (N CH2), 71.3 (C), 123.4
(benzo[b]thiophene CH), 125.8 (benzo[b]thiophene CH), 126.3 (ben-
zo[b]thiophene CH), 127.2 (benzo[b]thiophene CH), 130.0 (ben-
zo[b]thiophene C3), 140.7 (benzo[b]thiophene C), 141.6 ppm (ben-
zo[b]thiophene C) [Note, one quaternary carbon is missing, or two
carbons have identical shifts]. MS (LCMS ES+): m/z (%) 271 (100)
[M piperidine]
+, 356 (92) [M+H]
+. HRMS (ES+): calcd for
C23H34N1S1 [M+H]
+ 356.2406, found 356.2408 ( 0.32 ppm).
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